The CEA Registry Blog

By CEA Registry Team on 8/10/2017 3:48 PM
Peter J. Neumann and Joshua T. Cohen
Our newly published commentary in Pharmacoeconomics praises ICER’s revised value framework (and the organization itself) on many grounds, but also criticizes it on various aspects, including the manner in which it includes budget impact as a criterion for assessing drug prices (Neumann and Cohen, in press).
Our purpose here is to further elaborate on this point.  With regard to budget impact, ICER has maintained that their “value price” now reflects only cost-effectiveness considerations (which they refer to as “long-term value for money”).  We recognize that ICER has made the following public statements:
• The final ICER value-based price benchmark will be a single price based on the price needed to achieve the weighted incremental cost-effectiveness ratio determined by the appraisal committee at the public hearing. (Slide 17, ICER webinar, Value Framework Update)
• The purpose of our potential budget impact analyses and any “affordability and access alerts” are not to suggest a budget cap on spending for a particular drug, or for drugs as a category of spending in the US health care system. (Slide 25, ICER webinar, Value Framework Update)
• The ICER value framework is now structured (and depicted) without a formal integration of long-term value for money and short-term affordability.  Instead, the value framework suggests that consideration of these two elements is necessary to inform decisions seeking “sustainable access to high-value care for all patients.” (Overview of ICER Value Framework, Feb 1, 2017, pp. 10-11)
• Rather than try to estimate real-world uptake, ICER will present information that will allow stakeholders to ascertain the potential budget impact of a new service according to a wide range of assumptions on price and uptake. (Overview of ICER Value Framework, Feb 1, 2017, p. 18)
We believe these are positive steps.  However, because it retains a threshold ($915 million) against which total spending on a new drug is to be compared, we believe it would be inaccurate to say that ICER has downplayed or eliminated the budget impact constraint (ICER strongly objects to use of the term, “cap” – see Slide 25, ICER webinar, Value Framework Update).
Consider the following passage from ICER’s revised report:
• Given this goal, ICER will include as part of its final report an “affordability and access alert” if discussion among stakeholders at the meeting of ICER’s independent appraisal committees suggests that utilization driven by clinical need, at estimated net pricing, would exceed the budget impact threshold without active intervention by insurers and others to limit access to the treatment. (Overview of ICER Value Framework, Final report, 2017, p. 26)
That is, ICER’s new approach includes an “affordability and access alert” if “utilization… would exceed the budget impact threshold” (at utilization levels driven by clinical need).  In short, exceeding the $915 million budget threshold is a “red flag”.  Since the utilization level assumed is at the level of “clinical need,” the inclusion of such an alert implies the need to lower prices to avoid crossing this threshold.
As we emphasized in our piece, budget impact analyses are important and needed and should be calculated and disseminated, and we applauded ICER for advancing debates about affordability.  We continue to believe that retaining the $915 million per drug threshold is the issue, whatever terminology is used.  New statements and approaches about how the “red flag” is triggered may soften (or obscure) the matter, but the constraint and its impact remain.  And our point is that it doesn’t have to:  ICER could simply calculate and disseminate budget impact analyses with different assumptions about price, uptake, and time horizon, so that decision makers can draw their own conclusions, based on their own criteria (i.e., without ICER’s $915 million per drug criterion).
A final point regarding the wording in our original commentary: We stated, “This constraint means that spending on any new drug should not exceed $915 million per year, and, if it does, its ‘short-term affordability’ price should be adjusted downward to compensate.”  A better way to have phrased this may have been, “This constraint implies that spending on any new drug should not exceed $915 million per year…”  The only other recourse to avoid a budget threshold alert would be to reduce utilization, but that would imply withholding the drug from patients with clinical need.
Again, as we say in our commentary we applaud ICER on many grounds and have offered our views as constructive points to add to its worthy goals.
Neumann PJ and Cohen JT.  ICER’s Revised Value Assessment Framework for 2017–2019: A Critique.  Pharmacoeconomics.  In Press.  
By CEA Registry Team on 6/14/2017 2:10 PM
The Tufts Medical Center Cost-Effectiveness Analysis Registry ( has now been updated to include over half of all published cost-effectiveness analyses or CEAs from 2016.

Cost-per-QALY studies/Cost-utility studies (CUAs)
For years 1976-2016, we continue to catalogue cost-effectiveness analyses publishing cost per quality-adjusted life-years (Cost-per-QALY).
CEA Registry contents
The current upload adds the following to the database:
·         396 cost-effectiveness analyses articles published in 2016
o   179 full review
o   217 partial review
·         Among full review $/QALY articles:
o   601 cost-effectiveness ratios
o   966 utility weights
The full Registry now includes:
·         6,098 cost-effectiveness analyses articles published from 1976 through 2015 (47 cost-per-LY studies)
·         15,118 cost-effectiveness ratios
·         22,821 utility weights
CEA Registry website
Online search capabilities allow for public access to a select set of data from the registry, including utility weights and ratios.  CEVR’s premium access subscribers can access and download both the entire CEA Registry and the Tufts National Coverage Determination database, which provides detailed information on each national coverage decision.  Premium access subscribers can conduct advanced searches of the Registry data. 
If you are interested in becoming a sponsor, please contact Julie Lannon for more information.
Stay up-to-date on all the news from the CEA Registry by following us on Twitter @TuftsCEVR or Like Us on Facebook.
-          The CEA Registry Team
By CEA Registry Team on 5/30/2017 12:07 PM
A new study recently posted in Expert Review of Pharmacoeconomics & Outcomes Research, addresses the gap of knowledge between assumed time horizons across CEAs, and the relationship between the time horizons and estimated costs, benefits, and cost-effectiveness.
Among 782 articles identified from a systematic review using the Tufts Medical Center CEA Registry, 71% were found to use a long-term horizon (>5 years), 25% used a short-term horizon (≤5 years), and 4% used multiple, indicating that both a short-term and long-term horizon were used. Among studies that used multiple time horizons, the extension of the time horizon yielded more favorable incremental cost-effectiveness ratios (ICERs) in 19 cases and less favorable ICERs in 4 cases.
In addition to a literature review, three case studies were also developed with selected interventions to examine the relationship between time horizon and projected costs, benefits, and ICERs. These case studies showed the use of a longer time horizon also yielded more favorable ICERs.
This study demonstrated that the assumed time horizon in CEAs can considerably influence the value assessment of medical interventions. To capture all consequences, we encourage the use of time horizons that extends appropriately into the future.
Kim D, Wilkinson C, Pope E, Chambers J, Cohen J, Neumann P. The influence of time horizon on results of cost-effectiveness analyses. Expert Review of Pharmacoeconomics & Outcomes Research 2017 May: 1-9.
By CEA Registry Team on 5/8/2017 11:53 AM
This week we highlighted findings from recently published cost-effectiveness studies:
  • Cost-effectiveness of behavioral counseling for cardiovascular risk factors: Recommendations put forth by the U.S. Preventive Services Task Force (USPSTF) for behavioral counseling for adults with cardiovascular risk factors was found to be cost-effective, but varied greatly among subgroups (i.e. those with hypertension, impaired fasting glucose, or obesity). (24)
  • Cost-effectiveness of antiretroviral treatment (ART) same-day treatment: Same-day antiretroviral treatment (ART) initiation for HIV patients was found to be more effective, but slightly more expensive than standard initiation in a primary health clinic in South Africa. (26)
  • Variations in cost-effectiveness estimates about the effectiveness of PCSK-9 inhibitors: The primary driver behind various cost-effectiveness estimates for PCSK-9 inhibitors is due to assumptions about the risk of cardiovascular disease events. (47)
See below for a full list of all cost-utility studies and selected reviews and editorials published May 1-5, 2017.  To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry.  Follow us on Twitter (@TuftsCEVR) and Facebook.
1: Akers L, Rohde P, Stice E, Butryn ML, Shaw H. Cost-effectiveness of achieving  clinical improvement with a dissonance-based eating disorder prevention program. Eat Disord. 2017 May-Jun;25(3):263-272. doi: 10.1080/10640266.2017.1297107. Epub 2017 Mar 13.  PMID: 28287919.
2: Barlow BT, McLawhorn AS, Westrich GH. The Cost-Effectiveness of Dual Mobility Implants for Primary Total Hip Arthroplasty: A Computer-Based Cost-Utility Model.J Bone Joint Surg Am. 2017 May 3;99(9):768-777. PMID: 28463921.
3: Bertoldi EG, Stella SF, Rohde LEP, Polanczyk CA. Cost-effectiveness of anatomical and functional test strategies for stable chest pain: public health perspective from a middle-income country. BMJ Open. 2017 May 4;7(4):e012652. PMID: 28473507.
4: Bojke L, Manca A, Asaria M, Mahon R, Ren S, Palmer S. How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis. Pharmacoeconomics. 2017 May 3. PMID: 28470594.
5: Breeze PR, et al. The impact of Type 2 diabetes prevention programmes based on risk-identification and lifestyle intervention intensity strategies: a cost-effectiveness analysis. Diabet Med. 2017 May;34(5):632-640.PMID: 28075544.
6: Brown V, Moodie M, Cobiac L, Mantilla Herrera AM, Carter R. Obesity-related health impacts of fuel excise taxation- an evidence review and cost-effectiveness study. BMC Public Health. 2017 May 4;17(1):359. PMID: 28468618.
7: Chau SH, Sluiter RL, Kievit W, Wensing M, Teichert M, Hugtenburg JG. Cost Effectiveness of Gastroprotection with Proton Pump Inhibitors in Older Low-Dose Acetylsalicylic Acid Users in the Netherlands. Drugs Aging. 2017 May;34(5):375-386.PMID: 28361278.
8: Choi SE, Seligman H, Basu S. Cost Effectiveness of Subsidizing Fruit and Vegetable Purchases Through the Supplemental Nutrition Assistance Program. Am J Prev Med. 2017 May;52(5):e147-e155. Epub 2017 Jan 30. PMCID: PMC5401647.
9: Cutting KF. The cost-effectiveness of a novel soluble beta-glucan gel. J Wound Care. 2017 May 2;26(5):228-234. PMID: 28475444.
10: Delea TE, Weycker D, Atwood M, Neame D, Alvarez FP, Forget E, Langley JM, Chit A. Cost-effectiveness of alternate strategies for childhood immunization against meningococcal disease with monovalent and quadrivalent conjugate vaccines in Canada. PLoS One. 2017 May 4;12(5):e0175721. PMID: 28472165.
11: DePasse JV, Smith KJ, Raviotta JM, Shim E, Nowalk MP, Zimmerman RK, Brown ST.
Does Choice of Influenza Vaccine Type Change Disease Burden and Cost-Effectiveness in the United States? An Agent-Based Modeling Study. Am J Epidemiol. 2017 May 1;185(9):822-831. PMID:28402385.
12: Dilla T, Alexiou D, Chatzitheofilou I, Ayyub R, Lowin J, Norrbacka K. The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m(2). J Med Econ. 2017 May;20(5):443-452. PMID: 28008768.
13: Doble B, John T, Thomas D, Fellowes A, Fox S, Lorgelly P. Cost-effectiveness  of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing. Lung Cancer. 2017 May;107:22-35.PMID: 27316470.
14: Dunlop AJ, et al.Effectiveness and cost-effectiveness of unsupervised buprenorphine-naloxone for the treatment of heroin dependence in a randomized waitlist controlled trial.
Drug Alcohol Depend. 2017 May 1;174:181-191. PMID: 28371689.
15: Eijkemans MJC, Kersten FAM, Lintsen AME, Hunault CC, Bouwmans CAM, Roijen LH, Habbema JDF, Braat DDM. Cost-effectiveness of 'immediate IVF' versus 'delayed IVF': a prospective study. Hum Reprod. 2017 May 1;32(5):999-1008. PMID: 28204519.
16: Farr OM, Mantzoros CS. Treatment options to prevent diabetes in subjects with prediabetes: Efficacy, cost effectiveness and future outlook. Metabolism. 2017 May;70:192-195. PMID:28095990.
17: Gordon LG, James R, Tuffaha HW, Lowe A, Yaxley J. Cost-effectiveness analysis of multiparametric MRI with increased active surveillance for low-risk prostate cancer in Australia. J Magn Reson Imaging. 2017 May;45(5):1304-1315.PMID: 27726240.
18: Guest JF, Fuller GW, Vowden P. Clinical outcomes and cost-effectiveness of three different compression systems in newly-diagnosed venous leg ulcers in the UK. J Wound Care. 2017 May 2;26(5):244-254. PMID: 28475441.
19: Haukaas FS, Arnesen TM, Winje BA, Aas E. Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis. Eur J Health Econ. 2017 May;18(4):405-415. PMID:26970772.
20: Hauser RG, Campbell SM, Brandt CA, Wang S. Cost-Effectiveness Study of Criteria for Screening Cerebrospinal Fluid To Determine the Need for Herpes Simplex Virus PCR Testing. J Clin Microbiol. 2017 May;55(5):1566-1575.PMID: 28298450.
21: Hunter SA, Morris C, Nelson K, Snyder BJ, Poulton TB. Digital Breast Tomosynthesis: Cost-Effectiveness of Using Private and Medicare Insurance in Community-Based Health Care Facilities. AJR Am J Roentgenol. 2017 May;208(5):1171-1175. PMID:28177646.
22: Itzkowitz SH, Ahlquist DA. The Case for a Multitarget Stool DNA Test: A Closer Look at the Cost Effectiveness Model. Gastroenterology. 2017 May;152(6):1620-1621.PMID: 28384447.
23: Jensen C, Ross J, Feenstra TL, Raghoebar GM, Speksnijder C, Meijer HJA, Cune  MS. Cost-effectiveness of implant-supported mandibular removable partial dentures. Clin Oral Implants Res. 2017 May;28(5):594-601. PMID: 27080041.
24: Lin J, Zhuo X, Bardenheier B, Rolka DB, Gregg WE, Hong Y, Wang G, Albright A, Zhang P. Cost-effectiveness of the 2014 U.S. Preventive Services Task Force (USPSTF) Recommendations for Intensive Behavioral Counseling Interventions for Adults With Cardiovascular Risk Factors. Diabetes Care. 2017 May;40(5):640-646. PMID: 28213373.
25: Lo AO, Chan HL, Wong VW, Wong GL. Cost-effectiveness of the highly effective  direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong. J Gastroenterol Hepatol. 2017 May;32(5):1071-1078. PMID: 28449343.
26: Long LC, Maskew M, Brennan AT, Mongwenyana C, Nyoni C, Malete G, Sanne I, Fox MP, Rosen S. Initiating antiretroviral therapy for HIV at a patient's first clinic visit: A cost-effectiveness analysis of the RapIT randomized controlled trial. AIDS. 2017 May 1. PMID: 28463879.
27: Löfgren J, Matovu A, Wladis A, Ibingira C, Nordin P, Galiwango E, Forsberg BC. Cost-effectiveness of groin hernia repair from a randomized clinical trial comparing commercial versus low-cost mesh in a low-income country. Br J Surg. 2017 May;104(6):695-703. PMID:28206682.
28: Mamiya H, Tahara RK, Tolaney SM, Choudhry N, Najafzadeh M. Cost-Effectiveness of Palbociclib in Hormone Receptor-Positive Advanced Breast Cancer. Ann Oncol.2017 May 2. PMID:28472324.
29: McKirdy A, Imbuldeniya AM. The clinical and cost effectiveness of a virtual fracture clinic service: An interrupted time series analysis and before-and-after comparison. Bone Joint Res. 2017 May;6(5):259-269. PMID: 28473333.
30: Min JK, Gilmore A, Jones EC, Berman DS, Stuijfzand WJ, Shaw LJ, O'Day K, Danad I. Cost-effectiveness of diagnostic evaluation strategies for individuals with stable chest pain syndrome and suspected coronary artery disease. Clin Imaging. 2017 May - Jun;43:97-105. PMID: 28273654.
31: Moradi-Lakeh M, Yaghoubi M, Hajebi A, Malakouti SK, Vasfi MG. Cost-effectiveness of aftercare services for people with severe mental disorders: an analysis parallel to a randomised controlled clinical trial in Iran. Health Soc Care Community. 2017 May;25(3):1151-1159. PMID: 28147433.
32: Mori T, Crandall CJ, Ganz DA. Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan. Osteoporos Int. 2017 May;28(5):1733-1744. PMID: 28210776.
33: Mvundura M, Kokonya D, Abu-Haydar E, Okoth E, Herrick T, Mukabi J, Carlson L, Oguttu M, Burke T. Cost-effectiveness of condom uterine balloon tamponade to control severe postpartum hemorrhage in Kenya. Int J Gynaecol Obstet. 2017 May;137(2):185-191. PMID:28190262.
34: Olfert JA, Penz ED, Manns BJ, Mishra EK, Davies HE, Miller RF, Luengo-Fernandez R, Gao S, Rahman NM. Cost-effectiveness of indwelling pleural catheter compared with talc in malignant pleural effusion. Respirology. 2017 May;22(4):764-770. PMID:27983774.
35: Ong AA, Carroll WW, Nguyen SA, Gillespie MB. Cost-effectiveness of transfacial gland-preserving removal of parotid sialoliths. Laryngoscope. 2017 May;127(5):1080-1086. PMID:
36: Oyagüez I, Buti M, Brosa M, Rueda M, Casado MA. Cost-Effectiveness and Clinical Impact of Antiviral Strategies of HBeAg-Positive and -Negative Chronic Hepatitis B. Ann Hepatol. 2017 May - Jun;16(3):358-365. PMID: 28425405.
37: PLOS ONE Editors.. Expression of Concern: Adaptive Pacing, Cognitive Behaviour Therapy, Graded Exercise, and Specialist Medical Care for Chronic Fatigue Syndrome: A Cost-Effectiveness Analysis. PLoS One. 2017 May 2;12(5):e0177037. PMID: 28463341.
38: Pollom EL, et al. Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study. Radiology. 2017 May;283(2):460-468. PMID:28045603.
39: Prinja S, Bahuguna P, Faujdar DS, Jyani G, Srinivasan R, Ghoshal S, Suri V, Singh MP, Kumar R. Cost-effectiveness of human papillomavirus vaccination for adolescent girls in Punjab state: Implications for India's universal immunization program. Cancer. 2017 May 4. PMID: 28472550.
40: Rome K, Clark H, Gray J, McMeekin P, Plant M, Dixon J. Clinical effectiveness and cost-effectiveness of foot orthoses for people with established rheumatoid arthritis: an exploratory clinical trial. Scand J Rheumatol. 2017 May;46(3):187-193. PMID: 27466000.
41: Salazar J, Saxena V, Kahn JG, Roberts JP, Mehta N, Volk M, Lai JC.Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma. Transplantation. 2017 May;101(5):1001-1008.PMID: 27926593.
42: Shafie AA, Yeo HY, Coudeville L, Steinberg L, Gill BS, Jahis R, Amar-SinghHss. The Potential Cost Effectiveness of Different Dengue Vaccination Programmes in Malaysia: A Value-Based Pricing Assessment Using Dynamic Transmission Mathematical Modelling. Pharmacoeconomics. 2017 May;35(5):575-589. PMID: 28205150.
43: Silverstein A, Costas-Chavarri A, Gakwaya MR, Lule J, Mukhopadhyay S, Meara JG, Shrime MG. Laparoscopic Versus Open Cholecystectomy: A Cost-Effectiveness Analysis at Rwanda Military Hospital. World J Surg. 2017 May;41(5):1225-1233.PMID: 27905020.
44: Tapper EB, Afdhal NH, Curry MP. Before or After Transplantation? A Review of the Cost Effectiveness of Treating Waitlisted Patients With Hepatitis C. Transplantation. 2017 May;101(5):933-937.PMID: 28437385.
45: Tapper EB, Hughes MS, Buti M, Dufour JF, Flamm S, Firdoos S, Curry MP, Afdhal NH. The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis. Transplantation. 2017 May;101(5):987-995. PMID: 27495755.
46: Torgerson D. Cost effectiveness of public health interventions may be overestimated. BMJ. 2017 May 2;357:j2100. PMID:28465285.
47: Toth PP, Stevens W, Chou JW. Why have published studies of the cost effectiveness of PCSK-9 inhibitors yielded such markedly different results. J Med Econ. 2017 May 4:1-6. PMID: 28471246.
48: Veenstra DL, Guzauskas GF, Villa KF, Boudreau DM. The budget impact and cost-effectiveness of defibrotide for treatment of veno-occlusive disease with multi-organ dysfunction in patients post-hematopoietic stem cell transplant. J Med Econ. 2017 May;20(5):453-463. PMID: 28008770.
49: Venderink W, Govers TM, de Rooij M, Fütterer JJ, Sedelaar JPM. Cost-Effectiveness Comparison of Imaging-Guided Prostate Biopsy Techniques: Systematic Transrectal Ultrasound, Direct In-Bore MRI, and Image Fusion. AJR Am J Roentgenol. 2017 May;208(5):1058-1063. PMID: 28225639.
50: Whittington MD, Atherly AJ, Curtis DJ, Lindrooth RC, Bradley CJ, Campbell JD. Recommendations for Methicillin-Resistant Staphylococcus aureus Prevention in Adult ICUs: A Cost-Effectiveness Analysis. Crit Care Med. 2017 May 3. PMID: 28471887.
51: Zaidah AR, Mohammad NI, Suraiya S, Harun A. High burden of Carbapenem-resistant Enterobacteriaceae (CRE) fecal carriage at a teaching hospital: cost-effectiveness of screening in low-resource setting. Antimicrob Resist Infect Control. 2017 May 2;6:42. PMID: 28473912.
52: Zhang H, et al. Impact of nutrition support on clinical outcome and cost-effectiveness analysis in patients at nutritional risk: A prospective cohort study with propensity score matching. Nutrition. 2017 May;37:53-59. PMID: 28359363.
53: Zimmerman L, et al. Cost-Effectiveness of a Care Transition Intervention Among Multimorbid Patients. West J Nurs Res. 2017 May;39(5):622-642.PMID: 28322632.
By CEA Registry Team on 5/1/2017 4:02 PM
This week we highlighted findings from recently published cost-effectiveness studies:
  • Daclatasvir-sofosbuvir prevailing cost-effective treatment option for treating hepatitis C: Treating genotype 3 hepatitis C with daclatasvir-sofosbuvir was found to have lower costs and better effectiveness compared with sofosbuvir-ribavirin treatment. (26)
  • Age-based West Nile Virus vaccination program cost-effective: A West Nile Virus vaccination program focused on individuals at high-risk for severe disease across different ages was found to be more cost-effective than universal vaccination. (28)
See below for a full list of all cost-utility studies and selected reviews and editorials published April 17-28, 2017.  To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry.  Follow us on Twitter (@TuftsCEVR) and Facebook.
1: Ansaripour A, Thio HB, Maessen R, Redekop WK. The cost-effectiveness of blue-light therapy in the treatment of mild-to-moderate psoriasis. J Comp Eff Res. 2017 Apr 28. doi: 10.2217/cer-2017-0007. PMID: 28452226.
2: Athanasakis K, Boubouchairopoulou N, Tarantilis F, Tsiantou V, Kontodimas S, Kyriopoulos J. Cost-effectiveness of Ingenol Mebutate Gel for the Treatment of Actinic Keratosis in Greece. Clin Ther. 2017 Apr 24. PMID: 28449867.
3: Bickel K, Ozanne E. Importance of Costs and Cost Effectiveness of Palliative Care. J Oncol Pract. 2017 Apr 24:JOP2016019943. PMID: 28437151.
4: Burnham JM, Meta F, Lizzio V, Makhni EC, Bozic KJ. Technology assessment and cost-effectiveness in orthopedics: how to measure outcomes and deliver value in a constantly changing healthcare environment. Curr Rev Musculoskelet Med. 2017 Apr 19. PMID:28421386.
5: Cheng X, Zhao Y, Zhang X, Jin H, Min J. Health economic evaluation of immunization strategies of hepatitis E vaccine for elderly population. Hum Vaccin Immunother. 2017 Apr 27:0. PMID: 28448739.
6: Chiumento A, et al. Evaluating effectiveness and cost-effectiveness of a group psychological intervention using cognitive behavioral strategies for women with common mental disorders in
conflict-affected rural Pakistan: study protocol for a randomized controlled trial. Trials. 2017 Apr 26;18(1):190. PMID: 28441974.
7: Ferguson TW, Tangri N, Tan Z, James MT, Lavallee BDA, Chartrand CD, McLeod LL, Dart AB, Rigatto C, Komenda PVJ. Screening for chronic kidney disease in Canadian indigenous peoples is cost-effective. Kidney Int. 2017 Apr 19. PubMed PMID: 28433383.
8: Fluegge K. Cost-effectiveness of Wait Time Reduction in Behavioral Interventions for Autism. JAMA Pediatr. 2017 Apr 17. PMID: 28418516.
9: Foster NE, et al. The clinical and cost-effectiveness of stratified care for patients with sciatica: the SCOPiC randomised controlled trial protocol (ISRCTN75449581). BMC Musculoskelet Disord. 2017 Apr 26;18(1):172. PMID: 28441971.
10: Gosselin É, Lapré J, Lavoie S, Rhein S. Cost-effectiveness of introducing a nursing-based programme of ultrasound-guided peripheral venous access in a regional teaching hospital. J Nurs Manag. 2017 Apr 25. PMID: 28439999.
11: Gu S, Wang X, Qiao Q, Gao W, Wang J, Dong H. Cost-Effectiveness of Exenatide twice daily versus Insulin Glargine as add-on Therapy to Oral Anti-diabetic Agents in Type 2 Diabetes in China. Diabetes Obes Metab. 2017 Apr 28. PMID: 28452095.
12: Halpern JA, Chughtai B, Ghomrawi H. Cost-effectiveness of Common Diagnostic Approaches for Evaluation of Asymptomatic Microscopic Hematuria. JAMA Intern Med.
2017 Apr 17. PMID: 28418451.
13: Karapinar-Çarkıt F, et al.Cost-effectiveness of a transitional pharmaceutical care program for patients discharged from the hospital. PLoS One. 2017 Apr 26;12(4):e0174513.PMID: 28445474.
14: Kauf TL, Prabhu VS, Medic G, Borse RH, Miller B, Gaultney J, Sen SS, Basu A. Cost-effectiveness of ceftolozane/tazobactam compared withpiperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections. BMC Infect Dis. 2017 Apr 28;17(1):314. PMID: 28454524.
15: King J, Bress A, Bellows B. Cost-Effectiveness of Sacubitril-Valsartan in Patients Who Have Heart Failure With Reduced Ejection Fraction. Ann Intern Med. 2017 Apr 18;166(8):606-607. PMID: 28418551.
16: Koh KK. Cost Effectiveness of Nonstatin-to-Statin Therapy. J Am Coll Cardiol.2017 Apr 18;69(15):1995. PMID: 28408034.
17: Korman M, Wisløff T. Modelling the cost-effectiveness PCSK9 inhibitors vs.ezetimibe through LDL-C reductions in a Norwegian setting. Eur Heart J Cardiovasc Pharmacother. 2017 Apr 21. PMID: 28444187.
18: Kuyken W, et al. The effectiveness and cost-effectiveness of a mindfulness training programme in schools compared with normal school provision (MYRIAD): study protocol for a randomised controlled trial. Trials. 2017 Apr 26;18(1):194. PMID: 28446223.
19: Manfrin A, Tinelli M, Thomas T, Krska J. A cluster randomised control trial to evaluate the effectiveness and cost-effectiveness of the Italian medicines use review (I-MUR) for asthma patients. BMC Health Serv Res. 2017 Apr 24;17(1):300.PMID: 28438152.
20: Martin CA, et al. Improved outcome and cost effectiveness in ablation of persistent atrial fibrillation under general anaesthetic. Europace. 2017 Apr 21. PMID: 28444228.
21: Mitchell ED, Czoski Murray C, Meads D, Minton J, Wright J, Twiddy M. Clinical and cost-effectiveness, safety and acceptability of community intravenous antibiotic service models: CIVAS systematic review. BMJ Open. 2017 Apr 20;7(4):e013560. PMID: 28428184.
22: Moran D, Shrime MG, Nang S, Vycheth I, Vuthy D, Hong R, Padula WV, Park KB. Cost-Effectiveness of Craniotomy for Epidural Hematomas at a Major Government Hospital in Cambodia. World J Surg. 2017 Apr 25. PMID: 28444463.
23: Penner M. Cost Effectiveness of Wait Time Reduction in Behavioral Interventions for Autism-Reply. JAMA Pediatr. 2017 Apr 17. PMID: 28418501.
24: Rinkevich B. Rebutting the inclined analyses on the cost-effectiveness and feasibility of coral reef restoration. Ecol Appl. 2017 Apr 18. PMID: 28418173.
25: Robinson JG. Reply: Cost Effectiveness of Nonstatin-to-Statin Therapy. J Am
Coll Cardiol. 2017 Apr 18;69(15):1996. PMID: 28408035.
26: Saint-Laurent Thibault C, Moorjaney D, Ganz ML, Sill B, Hede S, Yuan Y, Gorsh B. Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States. J Med Econ. 2017 Apr 20:1-11. PMID: 28294645.
27: Sandhu AT, Ollendorf DA, Chapman RH, Pearson SD, Heidenreich PA. Cost-Effectiveness of Sacubitril-Valsartan in Patients Who Have Heart Failure With Reduced Ejection Fraction. Ann Intern Med. 2017 Apr 18;166(8):607-608. PMID: 28418550.
28: Shankar MB, Staples JE, Meltzer MI, Fischer M. Cost effectiveness of a targeted age-based West Nile virus vaccination program. Vaccine. 2017 Apr 26.PMID: 28456529.
29: Suh J, Kim B, Yang Y, Suh DC, Kim E. Cost effectiveness of influenza vaccination in patients with acute coronary syndrome in Korea. Vaccine. 2017 May 15;35(21):2811-2817. PMID: 28427844.
30: Suijker JJ, MacNeil-Vroomen JL, van Rijn M, Buurman BM, de Rooij SE, Moll van Charante EP, Bosmans JE. Cost-effectiveness of nurse-led multifactorial care to prevent or postpone new disabilities in community-living older people: Results of a cluster randomized trial. PLoS One. 2017 Apr 17;12(4):e0175272. PMID: 28414806.
31: Suárez-Llanos JP, et al. Clinical and cost-effectiveness analysis of early detection of patients at nutrition risk during their hospital stay through the new screening method CIPA: a study protocol. BMC Health Serv Res. 2017 Apr 20;17(1):292. PMID: 28424063.
32: Ten Eikelder MLG, et al. Comparing induction of labour with oral misoprostol or Foley catheter at term: cost effectiveness analysis of a randomised controlled multi-centre non-inferiority trial. BJOG. 2017 Apr 25. PMID: 28440898.
33: Toledo LAK, Noblat ACB, Nascimento HFD, Noblat LACB. Economic evaluation of
human albumin use in patients with nephrotic syndrome in four Brazilian public hospitals: pharmacoeconomic study. Sao Paulo Med J. 2017 Apr 20:0. PMID: 28443947.
34: Wang H, Yang L, Wang F, Zhang L. Strategies and cost-effectiveness evaluation of persistent albuminuria screening among high-risk population of chronic kidney disease. BMC Nephrol. 2017 Apr 18;18(1):135. PMID: 28420333.
35: Worthington J, et al. A randomised controlled trial to determine the clinical and cost effectiveness of thulium laser transurethral vaporesection of the prostate (ThuVARP) versus transurethral resection of the prostate (TURP) in the National Health Service (NHS) - the UNBLOCS trial: a study protocol for a randomised controlled trial. Trials. 2017 Apr 17;18(1):179. PMID: 28412960.
By CEA Registry Team on 5/1/2017 9:51 AM
Cost-effectiveness analysis (CEA) has been a major approach of evaluating the value of medical technology. The general idea is that if a technology is considered cost-effective (i.e., an incremental cost-effectiveness ratio (ICER) is lower than a specified cost-effectiveness threshold), the technology should be available for use in the health care. However, critical assumptions in the ICER are the use of an average treatment effect and complete adoption in practice. These assumptions are unlikely to be realistic – First, heterogeneity in treatment effect may exist; Second, heterogeneous effectiveness may lead to the differential adoption across subgroups; Third, the design of different policies (e.g., value-based insurance design) may also influence adoption behaviors in practice.   

In our new paper in Medical Decision Making, we proposed new metrics from ‘policy’ evaluation perspective by introducing weighted average ICERs that incorporates subgroup-specific adoption rates and heterogeneous effectiveness. We also extended this framework to consider parameter uncertainty to link with existing value of information metrics. This new framework will be useful to estimate the realized value of technologies based on how they will actually be used in practice.  Also, the proposed metrics may have a potential to improve the decision-making process by producing metrics that are better aligned with the specific policy decisions rather than just focusing on the evaluation of treatment alternatives.
Kim, D. D. and A. Basu "New Metrics for Economic Evaluation in the Presence of Heterogeneity: Focusing on Evaluating Policy Alternatives Rather than Treatment Alternatives." Medical Decision Making 0(0): 0272989X17702379.
By CEA Registry Team on 4/19/2017 4:04 PM
Better targeting of medical interventions is ever more important given the aging population , high prices of new technologies and limited budgets . Cost-effectiveness analysis (CEA) assesses the value of interventions, typically by comparing average population health gains to average costs.
Because intervention value differs across individuals, conventional CEA methods should be extended to address patient heterogeneity, when it can be predicted on the basis of pre-treatment characteristics.  One way to do so is to incorporate clinical risk prediction modeling and risk stratification into CEAs.  However, there are limitations to the accuracy and generalizability of clinical risk prediction models. 
In our new article in Medical Decision Making, we use simulation to assess how clinical risk prediction model performance may influence the expected value of individual risk-based versus population-based decision making in different scenarios. We conclude that individualizing treatment decisions using risk may produce substantial value, but also has the potential for net harm. Improvements in model discrimination generally increase the value derived from individualized information; however, when models are miscalibrated, under some circumstances they can lead to worse decisions than the population-wide strategies.  These results emphasize the importance of paying special attention to decision context in which models will be deployed and to model calibration, an often neglected aspect of predictive model validation. Caution is needed when transporting risk models to new settings. Whenever possible, risk models should be updated and recalibrated to ensure the accuracy of the risk information they yield.
Olchanski N, Cohen JT, Neumann PJ, Wong JB, Kent D. Understanding the Value of Individualized Information: The Impact of Poor Calibration or Discrimination in Outcome Prediction Models.  Medical Decision Making. 2017(in press).
By CEA Registry Team on 4/18/2017 1:08 PM
 This week we highlighted findings from recently published cost-effectiveness studies:
  • Offering patients a choice of influenza vaccine type decreases disease burden at a reasonable cost: Simulating a population of a large metropolitan area, a new study found that offering a choice of influenza vaccine type significantly reduced the number of influenza cases with favorable cost-effectiveness. (6)
  • Majority of literature on spinal cord stimulation for chronic back and limb pain demonstrates favorable cost-effectiveness: Review of the literature on spinal cord stimulation demonstrates an advantageous cost-effectiveness profile for treating chronic neuropathic pain when compared to reoperation and medical management. (10)
  • Progress in producing evidence to inform economic decision models in Health Technology Assessments of diagnostic tests: Appropriate meta-analysis methods in synthesizing evidence on diagnostic test accuracy for informing cost-effectiveness analyses have improved in recent years in the UK. (16)
See below for a full list of all cost-utility studies and selected reviews and editorials published April 10-14, 2017.  To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry.  Follow us on Twitter (@TuftsCEVR) and Facebook.
1: Algattas H, et al. Systematic Review of Safety and Cost-Effectiveness of Venous Thromboembolism Prophylaxis Strategies in Patients Undergoing Craniotomy for Brain Tumor. Neurosurgery. 2017 Apr 11. PMID: 28402497.
2: Anderson D, Lehmann J, Ecker T, Vosgerau S, Donatz V. [Cost effectiveness of
GnRH antagonists in patients with prostate cancer and cardiovascular risk: Comparative analysis against Leuprorelin by the Number Needed to Treat]. Urologe A. 2017 Apr 12. PMID: 28405705.
3: Carvalho AC, Leal F, Sasse AD. Cost-effectiveness of cetuximab and panitumumab
for chemotherapy-refractory metastatic colorectal cancer. PLoS One. 2017 Apr 12;12(4):e0175409. PMID: 28403233.
4: Clark LA, Whitmire S, Patton S, Clark C, Blanchette CM, Howden R. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease. J Med Econ. 2017 Apr 13:1-8. PMID: 28332417.
5: de Lorenzo-Pinto A, Herranz-Alonso A, Cuéllar-Basterrechea B, Bellón-Cano JM,
Sanjurjo-Sáez M, Bueno H. Clinical and Economic Impact of a Multisciplinary Intervention to Reduce Bleeding Risk in Patients With Acute Coronary Syndrome.Rev Esp Cardiol (Engl Ed). 2017 Apr 11. PMID:28411029.
6: DePasse JV, Smith KJ, Raviotta JM, Shim E, Nowalk MP, Zimmerman RK, Brown ST.
Does Choice of Influenza Vaccine Type Change Disease Burden and Cost-Effectiveness in the United States? An Agent-Based Modeling Study. Am J Epidemiol. 2017 Apr 10:1-10. PMID: 28402385.
7: Favato G, Easton T, Vecchiato R, Noikokyris E. Ecological validity of cost-effectiveness models of universal HPV vaccination: A systematic literature review. Vaccine. 2017 Apr 10. pii: S0264-410X(17)30445-0. PMID: 28408119.
8: Gee Kee E, Stockton K, Kimble RM, Cuttle L, McPhail SM. Cost-effectiveness of silver dressings for paediatric partial thickness burns: An economic evaluation from a randomized controlled trial. Burns. 2017 Apr 10. PMID: 28408145.
9: Greuter MJ, Schouten CS, Castelijns JA, de Graaf P, Comans EF, Hoekstra OS, de Bree R, Coupé VM. Cost-effectiveness of response evaluation after chemoradiation in patients with advanced oropharyngeal cancer using (18)F-FDG-PET-CT and/or diffusion-weighted MRI. BMC Cancer. 2017 Apr 11;17(1):256. PMID: 28399836.
10: Hoelscher C, Riley J, Wu C, Sharan A. Cost-Effectiveness Data Regarding Spinal Cord Stimulation for Low Back Pain. Spine (Phila Pa 1976). 2017 Apr 10.PMID: 28399549.
11: Kerr C. Cost-effectiveness of web-based therapy: what's it worth? Dev Med Child Neurol. 2017 Apr 11. PMID: 28398000.
12: Kohn CG, Zeichner SB, Chen Q, Montero AJ, Goldstein DA, Flowers CR. Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma. J Clin Oncol. 2017 Apr 10;35(11):1194-1202. PMID: 28221865.
13: McFerran E, O'Mahony JF, Fallis R, McVicar D, Zauber AG, Kee F. Evaluation of the Effectiveness and Cost-Effectiveness of Personalized Surveillance After Colorectal Adenomatous Polypectomy. Epidemiol Rev. 2017 Apr 10:1-13. PMID: 28402402.
14: Miyazaki S, et al. Quality of life and cost-utility of surgical treatment for patients with spinal
metastases: prospective cohort study. Int Orthop. 2017 Apr 10.PMID: 28396928.
15: Ruiz-Ramos J, et al. Cost-effectiveness analysis of implementing an antimicrobial stewardship program in critical care units. J Med Econ. 2017 Apr 13:1-8. PMID:28345481.
16: Shinkins B, Yang Y, Abel L, Fanshawe TR. Evidence synthesis to inform model-based cost-effectiveness evaluations of diagnostic tests: a methodological review of health technology assessments. BMC Med Res Methodol. 2017 Apr 14;17(1):56. PMID: 28410588.
17: Tomata Y, Watanabe T, Sugiyama K, Zhang S, Sugawara Y, Tsuji I. Effects of a Community-Based Program for Oral Health and Nutrition on Cost-Effectiveness by Preventing Disability in Japanese Frail Elderly: A Quasi-Experimental Study Using Propensity Score Matching. J Am Med Dir Assoc. 2017 Apr 12. PMID: 28412165.
By CEA Registry Team on 4/10/2017 1:11 PM
 This week we highlighted findings from recently published cost-effectiveness studies:
  • Patient centricity in cost-effectiveness analyses (CEAs) requires a statistical approach that accounts for patients' preferences and clinical and demographic characteristics: Two alternative approaches are proposed that use patient-level health-related utility and costs data to produce patient-centered cost-effectiveness. (4)
  • Increasing access to pregnancy tests highly effective at community level: Addition of low cost, easy-to-use urine pregnancy tests to maternal and reproductive services package offered in community health centers in Madagascar, Ethiopia, and Malawi, may offer a cost-effective solution to increase access and utilization of life-saving health services. (9)
  • Economic modeling of different interventions in women with BRCA1/2 mutations: Surgical preventive options for German women with BRCA1/2 mutation carriers result in a substantial gain of QALY/life years and potential cost savings when compared to no surgical prevention. (12)
See below for a full list of all cost-utility studies and selected reviews and editorials published April 3-7, 2017.  To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry.  Follow us on Twitter (@TuftsCEVR) and Facebook.
1: Berger BA, Cossio A, Saravia NG, Castro MD, Prada S, Bartlett AH, Pho MT. Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis. PLoS Negl Trop Dis. 2017 Apr 6;11(4):e0005459. PMID: 28384261.
2: Chan AY, Vadera S. Implementation of interdisciplinary neurosurgery morning huddle: cost-effectiveness and increased patient satisfaction. J Neurosurg. 2017 Apr 7:1-4. PMID:28387619.
3: Chen H, Chen L. Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China. PLoS One. 2017 Apr 5;12(4):e0175189. PMID: 28380022.
4: Goto D, Shih YT, Lecomte P, Olson M, Udeze C, Park Y, Mullins CD.Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis. Pharmacoeconomics. 2017 Apr 4. PMID: 28378193.
5: Havrilesky LJ, Moss HA, Chino J, Myers ER, Kauff ND. Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers  in BRCA1 mutation carriers. Gynecol Oncol. 2017 Apr 5. PMID: 28390820.
6: Itzkowitz SH, Ahlquist DA. The Case for a Multitarget Stool DNA Test: A Closer Look at the Cost Effectiveness Model. Gastroenterology. 2017 Apr 3.PMID: 28384447.
7: Jansen JP, Incerti D, Mutebi A, Peneva D, MacEwan JP, Stolshek B, Kaur P, Gharaibeh M, Strand V. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators. J Med Econ. 2017 Apr 5:1-12. PMID: 28294642.
8: Kerr M, Pears R, Miedzybrodzka Z, Haralambos K, Cather M, Watson M, Humphries
SE. Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK. Eur Heart J. 2017 Apr 6. PMID: 28387827.
9: Kolesar RJ, Audibert M, Comfort AB. Cost-effectiveness analysis and mortality impact estimation of scaling-up pregnancy test kits in Madagascar, Ethiopia and Malawi. Health Policy Plan. 2017 Apr 5. PMID: 28387867.
10: Lince-Deroche N, Fetters T, Sinanovic E, Devjee J, Moodley J, Blanchard K. The costs and cost effectiveness of providing first-trimester, medical and surgical safe abortion services in KwaZulu-Natal Province, South Africa. PLoS One. 2017 Apr 3;12(4):e0174615. PMID: 28369061.
11: Liu TW, et al. Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort. J Formos Med Assoc. 2017 Apr 4. PMID: 28389143.
12: Müller D, et al. Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation. Eur J Health Econ. 2017 Apr 5. PMID: 28382503.
13: Nedelcu M, Manos T, Gagner M, Eddbali I, Ahmed A, Noel P. Cost analysis of
leak after sleeve gastrectomy. Surg Endosc. 2017 Apr 4. PMID: 28378080.
14: Noben C, et al. Economic evaluation of an intervention program with the aim to improve at-work productivity for workers with rheumatoid arthritis. J Occup Health. 2017 Apr 5. PMID: 28381814.
15: Qiu J, Yu C, Ariyaratne TV, Foteff C, Ke Z, Sun Y, Zhang L, Qin F, Sanderson G. Cost-Effectiveness of Pediatric Cochlear Implantation in Rural China. Otol Neurotol. 2017 Apr 4. PMID: 28379918.
16: Ravikumar VK, et al. Cost-effectiveness of focused ultrasound, radiosurgery, and DBS for essential tremor. Mov Disord. 2017 Apr 3. PMID: 28370272.
17: Shim E. Cost-effectiveness of dengue vaccination in Yucatán, Mexico using a dynamic dengue transmission model. PLoS One. 2017 Apr 5;12(4):e0175020. PMID: 28380060.
18: Silver RM, Einerson BD. Cost-effectiveness analysis and Obstetrics: The time has come. BJOG. 2017 Apr 6. PMID: 28383770.
19: Takura T, Takei T, Nitta K. Cost-Effectiveness of Administering Rituximab for Steroid-Dependent Nephrotic Syndrome and Frequently Relapsing Nephrotic Syndrome: A Preliminary Study in Japan. Sci Rep. 2017 Apr 7;7:46036. PubMed PMID: 28387313.
20: Thilly N, et al. Cost-effectiveness of home telemonitoring in chronic kidney disease patients at different stages by a pragmatic randomized controlled trial (eNephro): rationale and study design. BMC Nephrol. 2017 Apr 5;18(1):126. PMID: 28381266.
21: Ting EE, Sander B, Ungar WJ. Systematic review of the cost-effectiveness of influenza immunization programs. Vaccine. 2017 Apr 4;35(15):1828-1843. PMID: 28284681.
22: Wikman-Jorgensen PE, et al. Microscopic observation drug-susceptibility assay vs Xpert(®) MTB/RIF for the diagnosis of tuberculosis in a rural African setting: a cost-utility analysis. Trop Med Int Health. 2017 Apr 5. PMID: 28380276.
By CEA Registry Team on 4/3/2017 1:59 PM
 This week we highlighted findings from recently published cost-effectiveness studies:
  • Apixaban therapy for atrial fibrillation provides clinical benefits at reasonable incremental cost: Apixaban compared with warfarin in patients with atrial fibrillation found to be reasonably cost-effective from the perspective of the US health care system. (4)
  • Review of cost-effectiveness analyses reveals relations between screening and vaccinating against human papillomavirus (HPV) infection: Variations in screening practices and valence of HPV vaccination had the largest implications in terms of cost-effectiveness. (7)
See below for a full list of all cost-utility studies and selected reviews and editorials published March 20-31, 2017.  To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry.  Follow us on Twitter (@TuftsCEVR) and Facebook.
1: Chan LH, Good DW, Laing K, Phipps S, Thomas BG, Keanie JY, Tolley DA, Cutress ML. Primary SWL Is an Efficient and Cost-Effective Treatment for Lower Pole Renal Stones Between 10 and 20 mm in Size: A Large Single Center Study. J Endourol. 2017 Mar 29. PubMed PMID:28355100.
2: Chau SH, Sluiter RL, Kievit W, Wensing M, Teichert M, Hugtenburg JG. Cost Effectiveness of Gastroprotection with Proton Pump Inhibitors in Older Low-Dose Acetylsalicylic Acid Users in the Netherlands. Drugs Aging. 2017 Mar 30. PMID: 28361278.
3: Chong HY, et al. Universal HLA-B*15:02 Screening a Cost-Effective Option in an Ethnically-Diverse Population? A Case Study of Malaysia. Br J Dermatol. 2017 Mar 27. PMID: 28346659.
4: Cowper PA, et al. Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol. 2017 Mar 29. PMID: 28355434.
5: Davis JC, et al. Economic evaluation of aerobic exercise training in older adults with vascular cognitive impairment: PROMoTE trial. BMJ Open. 2017 Mar 29;7(3):e014387. PMID: 28360247.
6: Ferket BS, Feldman Z, Zhou J, Oei EH, Bierma-Zeinstra SM, Mazumdar M. Impact of total knee replacement practice: cost effectiveness analysis of data from the Osteoarthritis Initiative. BMJ. 2017 Mar 28;356:j1131. PMID: 28351833.
7: Gervais F, Dunton K, Jiang Y, Largeron N. Systematic review of cost-effectiveness analyses for combinations of prevention strategies against human papillomavirus (HPV) infection: a general trend. BMC Public Health. 2017 Mar 28;17(1):283. PMID: 28351348.
8: Grimes CE, et al. Cost-Effectiveness of Two Government District Hospitals in Sub-Saharan Africa. World J Surg. 2017 Mar 27. PMID: 28349322.
9: Hope SF, et al. A systematic review of economic evaluations of population-based sodium
reduction interventions. PLoS One. 2017 Mar 29;12(3):e0173600. PMID: 28355231.
10: Hunt B, Mocarski M, Valentine WJ, Langer J. IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting. Diabetes Ther. 2017 Mar 27. PMID:28349444.
11: Karnon J, et al. A Cost-Effectiveness Model for Frail Older Persons: Development and Application to a Physiotherapy-Based Intervention. Appl Health Econ Health Policy. 2017 Mar 27. PMID: 28349499.
12: Lee TH, Kim W, Shin J, Park EC, Park S, Kim TH. Strategic Distributional Cost-Effectiveness Analysis for Improving National Cancer Screening Uptake in Cervical Cancer: A Focus on Regional Inequality in South Korea. Cancer Res Treat. 2017 Mar 30. PMID: 28361522.
13: Leung W, et al. Economic evaluation of an exercise-counselling intervention to enhance smoking cessation outcomes: The Fit2Quit trial. Tob Induc Dis. 2017 Mar 29;15:21. PMID:
14: Nishie A, et al. Cost-Effectiveness of EOB-MRI for Hepatocellular Carcinoma in Japan. Clin Ther. 2017 Mar 28. PMID: 28363694.
15: Pichler H, et al. Cost-Effectiveness of Defibrotide in the Prophylaxis of Veno-Occlusive Disease Following Pediatric Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017 Mar 27. PMID: 28359910.
16: Tamoschus D, Draexler K, Chang J, Ngai C, Madin-Warburton M, Pitcher A. Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany. Clin Drug Investig. 2017 Mar 30. PMID: 28361439.
17: Vega-Hernandez G, Wojcik R, Schlueter M. Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus  in the UK. Diabetes Ther. 2017 Mar 27. PMID: 28349443.
18: Zhou K, Wen F, Zhang P, Zhou J, Chen H, Zheng H, Yang Y, Li Q. Efficacy and cost-effectiveness of second-line chemotherapy in elderly patients with advanced gastric cancer. Clin Transl Oncol. 2017 Mar 28. PMID: 28353006.
19: Cost-effectiveness of regular versus irregular supportive periodontal therapy or tooth removal. Br Dent J. 2017 Mar 24;222(6):438. PMID: 28337007.
20: Achoki T, Lesego A. The imperative for systems thinking to promote access to medicines, efficient delivery, and cost-effectiveness when implementing health financing reforms: a qualitative study. Int J Equity Health. 2017 Mar 21;16(1):53. PMID: 28327143.
21: Brunetti ND, De Gennaro L, Caldarola P, Gaglione A, Di Biase M. Direct oral anticoagulants for the prevention of thromboembolic complications of atrial fibrillation: The more you pay, the less you spend? Int J Cardiol. 2017 Mar 22. PMID: 28363685.
22: Carlson JJ, Canestaro W, Ravelo A, Wong W. The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib. J Med Econ. 2017 Mar 23:1-7. PMID: 28332433.
23: Clark LA, Whitmire S, Patton S, Clark C, Blanchette CM, Howden R. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease. J Med Econ. 2017 Mar 23:1-17. PMID: 28332417.
24: Dieleman JM, et al. DExamethasone for Cardiac Surgery (DECS) Study Group. Long-term outcomes and cost effectiveness of high-dose dexamethasone for  cardiac surgery: a randomised trial. Anaesthesia. 2017 Mar 20. PMID: 28317094.
25: Earnshaw SR, McDade CL, Chu Y, Fleige LE, Sievenpiper JL. Cost-Effectiveness of Maintaining Daily Intake of Oat β-Glucan for Coronary Heart Disease Primary Prevention. Clin Ther. 2017 Mar 24. PMID: 28347513.
26: Edmond KM, Strobel NA, McAuley K, Geelhoed E, Hurt L. Economic evaluation of interventions delivered by primary care providers to improve neurodevelopment in children aged under 5 years: protocol for a scoping review. Syst Rev. 2017 Mar 21;6(1):59.PMID: 28327185.
27: Iscoe M, Lord R, Schulz J, Lee D, Cayea D, Pahwa A. Teaching medical students about cost-effectiveness. Clin Teach. 2017 Mar 21. PMID: 28322509.
28: Le LK, Barendregt JJ, Hay P, Sawyer SM, Paxton SJ, Mihalopoulos C. The modelled cost-effectiveness of cognitive dissonance for the prevention of anorexia nervosa and bulimia nervosa in adolescent girls in Australia. Int J Eat Disord. 2017 Mar 21. PMID: 28323355.
29: Luni Y, Borakati A, Matah A, Skeats K, Eedarapalli P. A prospective cohort study evaluating the cost-effectiveness of carbetocin for prevention of postpartum haemorrhage in caesarean sections. J Obstet Gynaecol. 2017 Mar 20:1-7.PMID: 28317421.
30: Matter-Walstra K, Schwenkglenks M, Dedes KJ. Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting. Breast Cancer Res Treat. 2017  Mar 21. PMID: 28321586.
31: Mercier G, Loureiro M, Georgescu V, Skalli EM, Nedelcu M, Ramadan M, Fabre JM, Lefebvre P, Nocca D. Surgical glue in laparoscopic sleeve gastrectomy: An initial experience and cost-effectiveness analysis. J Eval Clin Pract. 2017 Mar 21. PMID: 28322488.
32: Moriwaki K, Mouri M, Hagino H. Erratum to: Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. Osteoporos Int. 2017 Mar 21. PMID: 28324132.
33: Paquete AT, Miguel LS, Becker U, Pereira C, Pinto CG. Cost-Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients who are Unsuitable for Full-Dose Fludarabine-Based Therapy. Appl Health Econ Health Policy. 2017 Mar 24. PMID: 28342061.
34: Ramachandran A, Manabe Y, Rajasingham R, Shah M. Cost-effectiveness of CRAG-LFA screening for cryptococcal meningitis among people living with HIV in Uganda. BMC Infect Dis. 2017 Mar 23;17(1):225. PMID: 28335769.
35: Schwendicke F, Stolpe M. Cost-effectiveness of Different Post-retained Restorations. J Endod. 2017 Mar 23. pii: S0099-2399(17)30004-3. PMID: 28343930.
36: Tajeu GS, Mennemeyer S, Menachemi N, Weech-Maldonado R, Kilgore M. Cost-effectiveness of Antihypertensive Medication: Exploring Race and Sex Differences Using Data From the REasons for Geographic and Racial Differences in Stroke Study. Med Care. 2017 Mar 22. PMID: 28333708.
37: Tappenden P, Sadler S, Wildman M. An Early Health Economic Analysis of the Potential Cost Effectiveness of an Adherence Intervention to Improve Outcomes for Patients with Cystic Fibrosis. Pharmacoeconomics. 2017 Mar 23. PMID: 28337719.
38: Thom H, Jackson C, Welton N, Sharples L. Using Parameter Constraints to Choose State Structures in Cost-Effectiveness Modelling. Pharmacoeconomics. 2017  Mar 24.PMID: 28342114.
39: Whelan ME, Goode AD, Eakin EG, Veerman JL, Winkler EA, Hickman IJ, Reeves MM.
Erratum to: Feasibility, effectiveness and cost-effectiveness of a telephone-based weight loss program delivered via a hospital outpatient setting. Transl Behav Med. 2017 Mar 23. PMID: 28337721.
40: Wijnen BF, de Kinderen RJ, Lambrechts DA, Postulart D, Aldenkamp AP, Majoie MH, Evers SM. Long-term clinical outcomes and economic evaluation of the ketogenic diet versus care as usual in children and adolescents with intractable epilepsy. Epilepsy Res. 2017 Mar 21;132:91-99. PMID: 28364726.
By CEA Registry Team on 3/21/2017 10:22 AM
This week we highlighted findings from recently published cost-effectiveness studies:
  • Biomarker analysis potentially cost-saving diagnostic method for Alzheimer’s disease: When at least 1 in 11 patients has Alzheimer’s disease in a population, biomarker analysis is likely cost-effective. In areas where the prevalence of Alzheimer’s disease may be low, biomarker analysis is unlikely to be cost-effective at a willingness-to-pay threshold of $50,000/QALY gained. (6)
  • Review of cervical cancer screening methods cost-effectiveness in low- and middle-income countries: HPV testing and visual inspection with acetic acid (VIA) are more cost-effective screening methods than cytology for cervical cancer in low- and middle-income countries. (7)
  • Cost-effectiveness of identifying persons for early-stage chronic kidney disease screening: Chronic kidney disease risk scores may allow clinicians to cost-effectively identify a larger population for screening and potentially identify people at earlier stages of the disease than current practices. (13)
See below for a full list of all cost-utility studies and selected reviews and editorials published March 13-17, 2017.  To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry.  Follow us on Twitter (@TuftsCEVR) and Facebook.
1: Akers L, Rohde P, Stice E, Butryn ML, Shaw H. Cost-effectiveness of achieving  clinical improvement with a dissonance-based eating disorder prevention program. Eat Disord. 2017 Mar 13:1-10. PMID: 28287919.
2: Camacho EM, Ntais D, Jones S, Riste L, Morriss R, Lobban F, Davies LM. Cost-effectiveness of structured group psychoeducation versus unstructured group support for bipolar disorder: Results from a multi-centre pragmatic randomized controlled trial. J Affect Disord. 2017 Mar 15;211:27-36. PMID: 28086146.
3: Estades-Rubio FJ, et al. Knee Viscosupplementation: Cost-Effectiveness Analysis between Stabilized Hyaluronic Acid in a Single Injection versus Five Injections of Standard Hyaluronic Acid.Int J Mol Sci. 2017 Mar 17;18(3). PMID: 28304363.
4: Hauser RG, Campbell SM, Brandt CA, Wang S. Cost-Effectiveness Study of Criteria to Screen Herpes Simplex PCR Tests from Cerebrospinal Fluid. J Clin Microbiol. 2017 Mar 15. PMID: 28298450.
5: Jansen JP, et al. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators. J Med Econ. 2017 Mar 15:1-27. PMID: 28294642.
6: Lee SA, Sposato LA, Hachinski V, Cipriano LE. Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer's disease. Alzheimers Res Ther. 2017 Mar 16;9(1):18. PubMed PMID: 28302164.
7: Mezei AK, et al. Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: a systematic review. Int J Cancer. 2017 Mar 15. PMID: 28297074.
8: Rodin D, et al. Cost-Effectiveness Analysis of Radiation Therapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):709-717. PMID: 28244405.
9: Saint-Laurent Thibault C, Moorjaney D, Ganz ML, Sill B, Hede S, Yuan Y, Gorsh B. Cost-effectiveness of combination daclatasvir-sofosbuvir for the treatment of genotype 3 chronic hepatitis c infection in the United States. J Med Econ. 2017 Mar 15:1-20. PMID: 28294645.
10: Walsh EK, Hansen CR, Sahm LJ, Kearney PM, Doherty E, Bradley CP. Economic impact of medication error: a systematic review. Pharmacoepidemiol Drug Saf. 2017 Mar 13. PMID: 28295821.
11: Wan XM, Peng LB, Ma JA, Li YJ. Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectives. Cancer. 2017 Mar 16. PMID: 28301684.
12: Watt M, Dinh A, Le Monnier A, Tilleul P. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France. J Med Econ. 2017 Mar 16:1-9. PMID: 28299963.
13: Yarnoff BO, Hoerger TJ, Simpson SK, Leib A, Burrows NR, Shrestha SS, Pavkov
ME; Centers for Disease Control and Prevention CKD Initiative. The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease. BMC Nephrol. 2017 Mar 13;18(1):85. PMID: 28288579.


By CEA Registry Team on 3/13/2017 4:27 PM
 This week we highlighted findings from recently published cost-effectiveness studies:
  • Exercise program during cancer treatment cost-effective for colon cancer, but not breast cancer patients: An exercise intervention begun early after diagnosis was found to be more beneficial and less costly for colon cancer patients than for breast cancer patients in the Netherlands. (3)
  • Review of influenza immunization programs evaluate cost-effectiveness of universal versus targeted approaches: A universal approach over a targeted approach was found to be more cost-effective with an emphasis on vaccinating high-risk individuals. (6)
  • Different non-pharmacological treatments reviewed for knee osteoarthritis: A review of 11 non-pharmacological treatments for knee osteoarthritis in the UK found transcutaneous electrical nerve Stimulation (TENS) to be the most cost-effective. Among only higher quality RCTs reviewed, acupuncture was  cost-effective. (9)
See below for a full list of all cost-utility studies and selected reviews and editorials published March 6-10, 2017.  To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry.  Follow us on Twitter (@TuftsCEVR) and Facebook.
1: Buti M, Domínguez-Hernández R, Oyagüez I, Casado MA, Esteban R. Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis. J Viral Hepat. 2017 Mar 8. PMID: 28273410.
2: Hunt B, Mocarski M, Valentine WJ, Langer J. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA. Adv Ther. 2017 Mar 9. PMID: 28281218.
3: May AM, et al. Cost-effectiveness analysis of an 18-week exercise programme for patients with breast and colon cancer undergoing adjuvant chemotherapy: the randomised PACT study. BMJ Open. 2017 Mar 6;7(3):e012187. PMID: 28264824.
4: Moriwaki K, Mouri M, Hagino H. Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. Osteoporos Int. 2017 Mar 6. PMID: 28265718.
5: Schmier JK, Ong KL, Fonarow GC. Cost-Effectiveness of Remote Cardiac Monitoring With the CardioMEMS Heart Failure System. Clin Cardiol. 2017 Mar 8.PMID: 28272808.
6: Ting EE, Sander B, Ungar WJ. Systematic review of the cost-effectiveness of influenza immunization programs. Vaccine. 2017 Mar 8. PMID:28284681.
7: Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar 8. PMID: 28271250.
8: Wirth D, Dass R, Hettle R. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany. BMC Health Serv Res. 2017 Mar 8;17(1):182. PMID: 28270207.
9: Woods B, et al. Cost-effectiveness of adjunct non-pharmacological interventions for osteoarthritis of the knee. PLoS One. 2017 Mar 7;12(3):e0172749. PMID: 28267751.
10: Xu X, Yonkers KA, Ruger JP. Economic evaluation of a behavioral intervention versus brief advice for substance use treatment in pregnant women: results from a randomized controlled trial. BMC Pregnancy Childbirth. 2017 Mar 7;17(1):83. PMID: 28270105.
By CEA Registry Team on 3/13/2017 4:22 PM
This week we highlighted findings from recently published cost-effectiveness studies:
  • Herd-protection effects in CEAs have significant effect in estimated ICERs: In a quantitative comparative analysis of the incremental-cost-effectiveness-ratios for childhood vaccinations with vs without vaccine herd-protection, inclusion of herd-protection effects had a substantial impact in the estimated ICERs. (19) 
  • Three breast cancer treatments have similar outcomes, but cost-effectiveness varies by perspective: For selected patients, accelerated partial breast irradiation techniques were found to have the same outcomes as whole breast irradiation. From a healthcare perspective, whole breast radiation was found to be the least costly option, but accelerated partial breast irradiation was the least costly from a patient perspective. (31)
See below for a full list of all cost-utility studies and selected reviews and editorials published February 27- March 3, 2017.  To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry.  Follow us on Twitter (@TuftsCEVR) and Facebook.
1: Aitken E, Thomson P, Bainbridge L, Kasthuri R, Mohr B, Kingsmore D. A randomized controlled trial and cost-effectiveness analysis of early cannulation arteriovenous grafts versus tunneled central venous catheters in patients requiring urgent vascular access for hemodialysis. J Vasc Surg. 2017 Mar;65(3):766-774. PMID: 28236919.
2: Bergmann JN, et al. Outcomes and Cost-Effectiveness of Integrating HIV and Nutrition
Service Delivery: Pilots in Malawi and Mozambique. AIDS Behav. 2017 Mar;21(3):703-711. PMID: 27094787.
3: Bonsang-Kitzis H, et al. Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers. PLoS One. 2017 Feb 27;12(2): e0169962. PMID: 28241044.
4: Bozkaya D, Livingston T, Migliaccio-Walle K, Odom T. The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis. J Med Econ. 2017 Mar;20(3):297-302. PMID: 27822961.
5: Carter MJ, Gilligan AM, Waycaster CR, Schaum K, Fife CE. Cost effectiveness of adding clostridial collagenase ointment to selective debridement in individuals with stage IV pressure ulcers. J Med Econ. 2017 Mar;20(3):253-265. PMID: 27774840.
6: Chen LW, Wilson FA, Gregg A, Gupta N, Bekmuratova S, Palm D. Measuring the Cost and Value of Quality Improvement Initiatives for Local Health Departments. J Public Health Manag Pract. 2017 Mar 1.PMID: 28257401.
7: Chowers M, Shavit O. Economic evaluation of universal prenatal HIV screening compared with current 'at risk' policy in a very low prevalence country. Sex Transm Infect. 2017 Mar;93(2):112-117. PMID: 28213577.
8: Clarke CS, Hunter RM, Shemilt I, Serra-Sastre V. Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective. PLoS One. 2017 Mar 1;12(3):e0172731. PMID: 28248984.
9: Comans T, Mihala G, Sakzewski L, Boyd RN, Scuffham P. The cost-effectiveness of a web-based multimodal therapy for unilateral cerebral palsy: the Mitii randomized controlled trial. Dev Med Child Neurol. 2017 Mar 1. PMID: 28247406.
10: Coyle K, et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thromb Res. 2017 Mar;151:67-71.PMID: 28160670.
11: Fritz JM, Kim M, Magel JS, Asche CV. Cost-Effectiveness of Primary Care Management With or Without Early Physical Therapy for Acute Low Back Pain: Economic Evaluation of a Randomized Clinical Trial. Spine (Phila Pa 1976). 2017 Mar;42(5):285-290. PMID: 27270641.
12: Gao LL, Basta M, Kanchwala SK, Serletti JM, Low DW, Wu LC. Cost-effectiveness of microsurgical reconstruction for head and neck defects after oncologic resection. Head Neck. 2017 Mar;39(3):541-547.PMID: 27898195.
13: Gold MR, Padhiar A, Mealing S, Sidhu MK, Tsintzos SI, Abraham WT. Economic Value and Cost-Effectiveness of Cardiac Resynchronization Therapy Among Patients With Mild Heart Failure: Projections From the REVERSE Long-Term Follow-Up. JACC Heart Fail. 2017 Mar;5(3):204-212. PMID: 28254126.
14: Gyftopoulos S, Subhas N. Measuring Value, Outcomes, and Cost-Effectiveness in MSK Radiology: A Primer. Semin Musculoskelet Radiol. 2017 Feb;21(1):1-2. PMID: 28253526.
15: Hatch MD, Daniels SD, Glerum KM, Higgins LD. The cost effectiveness of vancomycin for preventing infections after shoulder arthroplasty: a break-even analysis. J Shoulder Elbow Surg. 2017 Mar;26(3):472-477. PMID: 27727049.
16: Hernandez L, Guo S, Toro-Diaz H, Carroll S, Syed Farooq SF. Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis. J Med Econ. 2017 Mar;20(3):228-238.  PMID: 27730845.
17: Hernández-Gago Y, Lombardero-Pin M, Ortega de la Cruz C, Maciuniak PA, Díez
Del Pino A. Cost effectiveness of a protocol using palivizumab in preterm infants. Farm Hosp. 2017 Mar 1;41(2):169-186. PMID: 28236796.
18: Hirsch JD, et al. Estimated Cost-Effectiveness, Cost Benefit, and Risk Reduction Associated with an Endocrinologist-Pharmacist Diabetes Intense Medical Management "Tune-Up" Clinic. J Manag Care Spec Pharm. 2017 Mar;23(3):318-326. PMID: 28230459.
19: Holubar M, Stavroulakis MC, Maldonado Y, Ioannidis JP, Contopoulos-Ioannidis D. Impact of vaccine herd-protection effects in cost-effectiveness analyses of childhood vaccinations. A quantitative comparative analysis. PLoS One. 2017 Mar 1;12(3):e0172414. PMID: 28249046.
20: Hwang HJ, Guidi MA, Curvale C, Lasa J, Matano R. Post-ERCP pancreatitis: early precut or pancreatic duct stent? A multicenter, randomized-controlled trial and cost-effectiveness analysis. Rev Esp Enferm Dig. 2017 Mar;109(3):174-179.PMID: 28185468.
21: Ibekwe E, Haigh C, Duncan F, Fatoye F. Economic impact of Routine Opt-out Antenatal HIV Screening: A Systematic Review. J Clin Nurs. 2017 Mar 2. PMID: 28252818.
22: Jeong YJ, et al. Analysis and comparison of the cost-effectiveness of statins according to the baseline low-density lipoprotein cholesterol level in Korea. J Clin Pharm Ther. 2017 Mar 1. PMID: 28251662.
23: Johns B, Doroshenko O, Tarantino L, Cowley P. The Cost-Effectiveness of Integrating HIV Counseling and Testing into Primary Health Care in the Ukraine. AIDS Behav. 2017 Mar;21(3):655-664. PMID: 27654316.
24: Kameda M, Yamada S, Atsuchi M, Kimura T, Kazui H, Miyajima M, Mori E,Ishikawa M, Date I; SINPHONI and SINPHONI-2 Investigators.. Cost-effectiveness analysis of shunt surgery for idiopathic normal pressure hydrocephalus based on the SINPHONI and SINPHONI-2 trials. Acta Neurochir (Wien). 2017 Mar 1. PMID: 28251346.
25: Kim DJ, Kim HS, Oh M, Kim EY, Shin JG. Cost Effectiveness of Genotype-Guided
Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the
Fee-for-Service System. Appl Health Econ Health Policy. 2017 Feb 28. PMID: 28247199.
26: Laguna MP. Re: Cost-Effectiveness of Management Options for Small Renal Mass:
A Systematic Review. J Urol. 2017 Mar;197(3 Pt 1):602-603. PMID: 28208510.
27: Lai K, Zhang C, Ke W, Gao Y, Zhou S, Liu L, Yang Y. Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China. Clin Drug Investig. 2017 Mar;37(3):233-247. PMID:
28: Liow MH, Agrawal K, Anderson DW, Freiberg AA, Rubash HE, Kwon YM. Unsuspected
Malignancies in Routine Femoral Head Histopathologic Examination During Primary Total Hip Arthroplasty: Cost-Effectiveness Analysis. J Arthroplasty. 2017 Mar;32(3):735-742. PMID: 27697361.
29: Liu CY, Chen HC. Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan. Clin Drug Investig. 2017 Mar;37(3):285-293. PMID: 27988835.
30: Martinez JM, Anene A, Bentley TG, Cangelosi MJ, Meckley LM, Ortendahl JD, Montero AJ. Cost Effectiveness of Metal Stents in Relieving Obstructive Jaundice in Patients with Pancreatic Cancer. J Gastrointest Cancer. 2017 Mar;48(1):58-65.PMID: 28025817.
31: McGuffin M, Merino T, Keller B, Pignol JP. Who Should Bear the Cost of Convenience? A Cost-effectiveness Analysis Comparing External Beam and Brachytherapy Radiotherapy Techniques for Early Stage Breast Cancer. Clin Oncol (R Coll Radiol). 2017 Mar;29(3):e57-e63. PMID: 27956335.
32: Mock C. Strengthening the Methodologic Rigor of Cost-Effectiveness Studies in Global Surgery. World J Surg. 2017 Mar 2. PMID: 28255627.
33: Naunheim MR, Song PC, Franco RA, Alkire BC, Shrime MG. Surgical management of
bilateral vocal fold paralysis: A cost-effectiveness comparison of two treatments. Laryngoscope. 2017 Mar;127(3):691-697. PMID: 27578299.
34: Ophuis RH, Lokkerbol J, Heemskerk SC, van Balkom AJ, Hiligsmann M, Evers SM.
Cost-effectiveness of interventions for treating anxiety disorders: A systematic review. J Affect Disord. 2017 Mar 1;210:1-13. PMID: 27988373.
35: Padula WV, Millis MA, Worku AD, Pronovost PJ, Bridges JF, Meltzer DO. Individualized cost-effectiveness analysis of patient-centered care: a case series of hospitalized patient preferences departing from practice-based guidelines. J Med Econ. 2017 Mar;20(3):288-296. PMID: 27786569.
36: Pambrun T, et al. Contact-force guided single-catheter approach for pulmonary vein isolation: Feasibility, outcomes, and cost-effectiveness. Heart Rhythm. 2017 Mar;14(3):331-338. PMID: 27940124.
37: Pascacio-Villafán C, Birke A, Williams T, Aluja M. Modeling the cost-effectiveness of insect rearing on artificial diets: A test with a tephritid fly used in the sterile insect technique. PLoS One. 2017 Mar 3;12(3):e0173205. PMID: 28257496.
38: Prinja S, Kaur G, Malhotra P, Jyani G, Ramachandran R, Bahuguna P, Varma S. Cost-Effectiveness of Autologous Stem Cell Treatment as Compared to Conventional Chemotherapy for Treatment of Multiple Myeloma in India. Indian J Hematol Blood Transfus. 2017 Mar;33(1):31-40. PMID: 28194053.
39: Qin G, Zhuang X. Cost-effectiveness of augmenting current perinatal hepatitis B prevention program with maternal antiviral therapy. Hepatology. 2017 Mar;65(3):1074-1075. PMID: 27785834.
40: Requena-Méndez A, et al. Cost-effectiveness of Chagas disease screening in Latin American migrants at primary health-care centres in Europe: a Markov model analysis. Lancet Glob Health. 2017 Feb 27. PMID: 28256340.
41: Romero-Sanchiz P, et al. Economic evaluation of a guided and unguided internet-based CBT intervention for major depression: Results from a multi-center, three-armed randomized controlled trial conducted in primary care. PLoS One. 2017 Feb 27;12(2):e0172741. PMID: 28241025.
42: Samur S, et al. Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis. Hepatology. 2017 Mar;65(3):920-928. PMID: 27906472.
43: Sawad AB, Seoane-Vazquez E, Rodriguez-Monguio R, Turkistani F. Cost-effectiveness of different strategies for treatment relapsing-remitting multiple sclerosis. J Comp Eff Res. 2017 Mar;6(2):97-108. PMID: 28118731.
44: Shanahan M, Hughes CE, McSweeney T, Griffin BA. Alternate policing strategies: Cost-effectiveness of cautioning for cannabis offences. Int J Drug Policy. 2017 Mar;41:140-147. PMID:28139329.
45: Smith GA. Erratum: Screening via CT angiogram after traumatic cervical spine fractures: narrowing imaging to improve cost effectiveness. Experience of a Level I trauma center. J Neurosurg Spine. 2017 Mar;26(3):404. PMID: 27911228.
46: Smith WB 2nd, Steinberg J, Scholtes S, Mcnamara IR. Medial compartment knee osteoarthritis: age-stratified cost-effectiveness of total knee arthroplasty, unicompartmental knee arthroplasty, and high tibial osteotomy. Knee Surg Sports Traumatol Arthrosc. 2017 Mar;25(3):924-933. PMID: 26520646.
47: Sun D, McCarthy TJ, Liberman DB. Cost-Effectiveness of Watchful Waiting in Acute Otitis Media. Pediatrics. 2017 Mar 3. PMID: 28258074.
48: Sun Y, You W, Almeida F, Estabrooks P, Davy B. The Effectiveness and Cost of Lifestyle Interventions Including Nutrition Education for Diabetes Prevention: A Systematic Review and Meta-Analysis. J Acad Nutr Diet. 2017 Mar;117(3):404-421.e36. PMID: 28236962.
49: Tufail A, et al. Automated Diabetic Retinopathy Image Assessment Software: Diagnostic
Accuracy and Cost-Effectiveness Compared with Human Graders. Ophthalmology. 2017 Mar;124(3):343-351. PMID: 28024825.
50: Visser JJ, Oei EH, Hunink MG. Using Cost-Effectiveness Analysis to Measure Value in Musculoskeletal Imaging. Semin Musculoskelet Radiol. 2017 Feb;21(1):37-42. PMID: 28253532.
51: Wali AR, Park CC, Brown JM, Mandeville R. Analyzing cost-effectiveness of ulnar and median nerve transfers to regain forearm flexion. Neurosurg Focus. 2017 Mar;42(3):E11. PMID: 28245686.
52: Wei CY, Quek RG, Villa G, Gandra SR, Forbes CA, Ryder S, Armstrong N, Deshpande S, Duffy S, Kleijnen J, Lindgren P. A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies. Pharmacoeconomics. 2017 Mar;35(3):297-318. PMID: 27785772.
53: Wojcik R, Lowin J, Vilardell D, Maeso S, Ruiz L, Lear JT, Morton C. The cost-effectiveness of 5-FU-SA in the treatment of actinic keratoses of the face and scalp in the UK secondary care setting. J Med Econ. 2017 Mar;20(3):221-227. PMID: 27715356
By CEA Registry Team on 2/28/2017 10:35 AM
 This week we highlighted findings from recently published cost-effectiveness studies:
  • Text message-based health intervention predicted to improve health and be cost-saving: Using text messages to send health-related advice, motivation, information, and support to patients with coronary heart disease is expected to promote better health outcomes and overall cost savings in the Australian health care system. (1)
  • Cost-effectiveness of a H. pylori serology-based screening program found to be favorable: In New Zealand, a nationwide screening for H. pylori was found to avert future gastric cancer cases over a lifetime at a favorable cost-effective threshold. (11).
  • Gap in evidence on the cost-effectiveness of genetic diagnostic testing for Autism Spectrum Disorder: An urgent need for economic evaluations on genetic test for Autism Spectrum Disorder was revealed after a systematic review found a lack of evidence available. (14)
See below for a full list of all cost-utility studies and selected reviews and editorials published February 20-24, 2017.  To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry.  Follow us on Twitter (@TuftsCEVR) and Facebook.
1: Burn E, et al. Cost-effectiveness of a text message programme for the prevention of recurrent cardiovascular events. Heart. 2017 Feb 24. PMID: 28235776.
2: Chetty M, Kenworthy JJ, Langham S, Walker A, Dunlop WC. A systematic review of health economic models of opioid agonist therapies in maintenance treatment of non-prescription opioid dependence. Addict Sci Clin Pract. 2017 Feb 24;12(1):6.PMID: 28235415.
3: Duarte A, Walker S, Littlewood E, Brabyn S, Hewitt C, Gilbody S, Palmer S. Cost-effectiveness of computerized cognitive-behavioural therapy for the treatment of depression in primary care: findings from the Randomised Evaluation of the Effectiveness and Acceptability of Computerised Therapy (REEACT) trial. Psychol Med. 2017 Feb 23:1-11. PMID: 28228182.
4: Franken MD, et al. Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer. Eur J Cancer. 2017 Feb 23;75:204-212. PMID: 28237866.
5: Hassmiller Lich K, et al. Cost-Effectiveness Analysis of Four Simulated Colorectal Cancer
Screening Interventions, North Carolina. Prev Chronic Dis. 2017 Feb 23;14:E18. PMID: 28231042.
6: Johnsen NV, Penson DF, Reynolds WS, Milam DF, Dmochowski RR, Kaufman MR. Cost-effective management of pelvic fracture urethral injuries. World J Urol. 2017 Feb 22. PMID:
7: Kohn CG, Zeichner SB, Chen Q, Montero AJ, Goldstein DA, Flowers CR. Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma. J Clin Oncol. 2017 Feb 21:JCO2016696336. PMID: 28221865.
8: Larsen B, Marcus B, Pekmezi D, Hartman S, Gilmer T. A Web-Based Physical Activity Intervention for Spanish-Speaking Latinas: A Costs and Cost-Effectiveness Analysis. J Med Internet Res. 2017 Feb 22;19(2):e43. PMID: 28228368.
9: Lian JX, McGhee SM, So C, Chau J, Wong CK, Wong WC, Lam CL. Five-year cost-effectiveness of Patient Empowerment Programme (PEP) for type 2 diabetes mellitus in primary care. Diabetes Obes Metab. 2017 Feb 23. PMID: 28230312.
10: Mezquita-Raya P, et al. Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain. Diabetes Ther. 2017 Feb 21. PMID: 28224463.
11: Teng AM, Kvizhinadze G, Nair N, McLeod M, Wilson N, Blakely T. A screening program to test and treat for Helicobacter pylori infection: Cost-utility analysis by age, sex and ethnicity. BMC Infect Dis. 2017 Feb 20;17(1):156. PMID: 28219322.
12: Venderink W, Govers TM, de Rooij M, Fütterer JJ, Sedelaar JP. Cost-Effectiveness Comparison of Imaging-Guided Prostate Biopsy Techniques: Systematic Transrectal Ultrasound, Direct In-Bore MRI, and Image Fusion. AJR Am J Roentgenol. 2017 Feb 22:1-6. PMID: 28225639.
13: von Dach E, Morel CM, Murthy A, Pagani L, Macedo-Vinas M, Olearo F, Harbarth S. Comparing The Cost-Effectiveness Of Linezolid To Trimethoprim/Sulfamethoxazole Plus Rifampicin For The Treatment Of MRSA Infection: A Health-Care System Perspective. Clin Microbiol Infect. 2017 Feb 20. PMID: 28232163.
14: Ziegler A, Rudolph-Rothfeld W, Vonthein R. Genetic Testing for Autism Spectrum Disorder is Lacking Evidence of Cost-Effectiveness. A Systematic Review. Methods Inf Med. 2017 Feb 21. PMID: 28220926.
By CEA Registry Team on 2/21/2017 4:36 PM
By Josh Cohen, Jordan Anderson, and Peter Neumann
Our  new article in Value in Health examines three prominent value frameworks designed to help evaluate therapies: Memorial Sloan Kettering Cancer Center’s DrugAbacus, the American Society of Clinical Oncologists (ASCO) framework, and the Institute for Clinical and Economic Review (ICER) framework. Our paper develops a series of case studies that illustrate areas where the frameworks are not yet well aligned with certain notions of value, namely if value is proportional to a therapy’s benefit, if value reflects factors relevant to framework users, if weights reflect user preferences, and if value estimates used to inform therapy prices reflect per-person benefit. We conclude that although the value frameworks we reviewed capture value in a way that is important to various audiences, they are not always logical or consistent. 
To find out how you can learn more by participating in our research Center’s Value Frameworks Workshop, contact Julie Lannon (
1: Cohen J, Anderson J, Neumann P. Three Sets of Case Studies Suggest Logic and Consistency Challenges with Value Frameworks. Value in Health 2017;20:193-199.
By CEA Registry Team on 2/14/2017 9:53 AM
This week we highlighted findings from recently published cost-effectiveness studies:
  • Framework for geographic targeting based on cost-effectiveness applied to priority setting in malaria control: An approach using targeted geographic data to estimate intervention costs and effects is recommended for implementing malaria interventions in order to maximize available resources and work towards elimination (9)
  • Review of cost-effectiveness models in breast cancer screening highlights structural and methodological approaches: A systematic review revealed that models used in cost-effectiveness analysis employed varying disease progression assumptions and imprecise utility estimates (17)
 See below for a full list of all cost-utility studies and selected reviews and editorials published February 6-10, 2017.  To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry.  Follow us on Twitter (@TuftsCEVR) and Facebook.
1: Achana F, Petrou S, Khan K, Gaye A, Modi N; Medicines for Neonates Investigators. A methodological framework for assessing agreement between cost-effectiveness outcomes estimated using alternative sources of data on treatment costs and effects for trial-based economic evaluations. Eur J Health Econ. 2017 Feb 9. PMID: 28180977.
2: Bearz A, Berretta M, Tirelli U. Clinical Effectiveness and Cost-Effectiveness  of Target Therapies for Adult Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Systematic Review. Curr Cancer Drug Targets. 2017 Feb 6. PMID:28176647.
3: Bierbaum M, Schöffski O, Schliemann B, Kösters C. Cost-utility analysis of dynamic intraligamentary stabilization versus early reconstruction after rupture of the anterior cruciate ligament. Health Econ Rev. 2017 Dec;7(1):8. PMID: 28168633.
4: Brockbank J, Wolowacz S. Economic Evaluations of New Oral Anticoagulants for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement: A Systematic Review. Pharmacoeconomics. 2017 Feb 10. PMID: 28185212.
5: Cadier B, et al. Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States. Hepatology. 2017 Feb 8. PubMed PMID: 28176349.
6: Capri S, Porta C, Delea TE. Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective. Clin Ther. 2017 Feb 9. PMID: 28189363.
7: Coppola A, D'Ausilio A, Aiello A, Amoresano S, Toumi M, Mathew P, Tagliaferri A; Potter Study Group.. Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy. Haemophilia. 2017 Feb 8. PMID: 28181369.
8: Cowie MR, Simon M, Klein L, Thokala P. The cost-effectiveness of real-time pulmonary artery pressure monitoring in heart failure patients: a European perspective. Eur J Heart Fail. 2017 Feb 7. PMID: 28176424.
9: Drake TL, Lubell Y, Kyaw SS, Devine A, Kyaw MP, Day NP, Smithuis FM, White LJ. Geographic Resource Allocation Based on Cost Effectiveness: An Application to Malaria Policy. Appl Health Econ Health Policy. 2017 Feb 10.  PMID: 28185133.
10: Hunter SA, Morris C, Nelson K, Snyder BJ, Poulton TB. Digital Breast Tomosynthesis: Cost-Effectiveness of Using Private and Medicare Insurance in Community-Based Health Care Facilities. AJR Am J Roentgenol. 2017 Feb 8:1-5. PMID: 28177646.
11: Hwang HJ, Guidi MA, Curvale C, Lasa J, Matano R. Post-ERCP pancreatitis: early precut or pancreatic duct stent? A multicenter, randomized-controlled trial and cost-effectiveness analysis. Rev Esp Enferm Dig. 2017 Feb 10. PMID: 28185468.
12: Kim JF, Nwaru BI, McCleary N, Stoddart A, Sheikh A. Investigating the accuracy, risk impact, and cost-effectiveness of component-resolved diagnostic test for food allergy: a systematic review protocol. NPJ Prim Care Respir Med.2017 Dec;27(1):10. PMID: 28184046.
13: Lachance CC, Jurkowski MP, Dymarz AC, Robinovitch SN, Feldman F, Laing AC, Mackey DC. Compliant flooring to prevent fall-related injuries in older adults: A scoping review of biomechanical efficacy, clinical effectiveness, cost-effectiveness, and workplace safety. PLoS One. 2017 Feb 6;12(2):e0171652. PMID: 28166265.
14: Orenstein EW, et al. Cost-effectiveness of maternal influenza immunization in Bamako, Mali: A decision analysis. PLoS One. 2017 Feb 7;12(2):e0171499. PMID: 28170416.
15: Pepe A, et al. Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective. Clin Drug Investig. 2017 Feb 10. PMID: 28185140.
16: Schechner V, Carmeli Y, Leshno M. A mathematical model of Clostridium difficile transmission in medical wards and a cost-effectiveness analysis comparing different strategies for laboratory diagnosis and patient isolation. PLoS One. 2017 Feb 10;12(2):e0171327. PMID: 28187144.
17: Schiller-Frühwirth IC, Jahn B, Arvandi M, Siebert U. Cost-Effectiveness Models in Breast Cancer Screening in the General Population: A Systematic Review. Appl Health Econ Health Policy. 2017 Feb 10. PMID: 28185134.
18: Seki Y, et al. Erratum to: A feasibility study of the clinical effectiveness and cost-effectiveness of individual cognitive behavioral therapy for panic disorder in a Japanese clinical setting: an uncontrolled pilot study. BMC Res Notes. 2017 Feb 6;10(1):86. PMID: 28166808.
19: Shah L, Rojas M, Mori O, Zamudio C, Kaufman JS, Otero L, Gotuzzo E, Seas C, Brewer TF. Cost-effectiveness of active case-finding of household contacts of pulmonary tuberculosis patients in a low HIV, tuberculosis-endemic urban area of Lima, Peru. Epidemiol Infect. 2017 Feb 6:1-11. PMID: 28162099.
20: Ten Haaf K, et al. Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada. PLoS Med. 2017 Feb 7;14(2):e1002225. PMID: 28170394.
21: Xu S, Immaneni S, Hazen GB, Silverberg JI, Paller AS, Lio PA. Cost-effectiveness of Prophylactic Moisturization for Atopic Dermatitis. JAMA Pediatr. 2017 Feb 6;171(2):e163909. PMID: 27918774.
22: Yue WW, Wang SR, Lu F, Li XL, Xu HX, Sun LP, Guo LH, He YP, Wang D, Yin ZQ. Corrigendum: Quality of Life and Cost-Effectiveness of Radiofrequency Ablation versus Open Surgery for Benign Thyroid Nodules: a retrospective cohort study. Sci Rep. 2017 Feb 10;7:41342. PMID: 28186108.
By CEA Registry Team on 2/6/2017 4:57 PM

This week we highlighted findings from recently published cost-effectiveness studies:

  • New insights into methodological derivation of thresholds used in global health: New paper reviews the underlying concepts of CEA thresholds, the derivation of the one and three times GDP per capital multipliers, and suggestions for improvement in global health research (46)
  • Use of specialized oral nutritional supplements suggests considerable cost-effectiveness: Providing specialized oral nutritional supplements to prevent and combat malnutrition in older hospitalized patients was found to extend the life of patients with favorable cost-effectiveness (58)
See below for a full list of all cost-utility studies and selected reviews and editorials published January 30 – February 3, 2017.  To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry.  Follow us on Twitter (@TuftsCEVR) and Facebook.
1: Aichmair A, et al. Cost-effectiveness of conservative versus surgical treatment strategies of lumbar spinal stenosis in the Swiss setting: analysis of the prospective multicenter Lumbar Stenosis Outcome Study (LSOS). Eur Spine J. 2017 Feb;26(2):501-509. PMID: 28040872.
2: Baras Shreibati J, Goldhaber-Fiebert JD, Banerjee D, Owens DK, Hlatky MA. Cost-Effectiveness of Left Ventricular Assist Devices in Ambulatory Patients With Advanced Heart Failure. JACC Heart Fail. 2017 Feb;5(2):110-119. PMID: 28017351.
3: Barbosa C, Cowell A, Dowd W, Landwehr J, Aldridge A, Bray J. The cost-effectiveness of brief intervention versus brief treatment of Screening, Brief Intervention and Referral to Treatment (SBIRT) in the United States. Addiction. 2017 Feb;112 Suppl 2:73-81. PMID:28074567.
4: Bardach AE, et al. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model. BMC Public Health. 2017 Feb 2;17(1):152. PMID: 28148228.
5: Chen HD, Zhou J, Wen F, Zhang PF, Zhou KX, Zheng HR, Yang Y, Li Q. Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer. J Cancer Res Clin Oncol. 2017 Feb;143(2):361-368. PMID: 27798730.
6: Choi SE, Seligman H, Basu S. Cost Effectiveness of Subsidizing Fruit and Vegetable Purchases Through the Supplemental Nutrition Assistance Program. Am J Prev Med. 2017 Jan 30. PMID: 28153648.
7: Claxton L, Hodgson R, Taylor M, Malcolm B, Pulikottil Jacob R. Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom. Pharmacoeconomics. 2017 Feb;35(2):237-248. PMID: 27787744.
8: Connell NT, Abel GA, Connors JM. Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis. Thromb Res. 2017 Feb;150:53-58. PMID: 28039844.
9: Costa D, Peixoto Lima R. Cost-effectiveness of ambulatory blood pressure monitoring in the management of hypertension. Rev Port Cardiol. 2017 Jan 31. English, Portuguese. PMID: 28159431.
10: Coyle D. Increasing the methodological quality and relevance of cost effectiveness analysis. Thromb Res. 2017 Feb;150:121-122. PMID: 28007401.
11: Cradock AL, et al. Using cost-effectiveness analysis to prioritize policy and programmatic approaches to physical activity promotion and obesity prevention in childhood. Prev Med. 2017 Feb;95S:S17-S27. PMID: 27773710.
12: Critchlow S, Hirst M, Akehurst R, Phillips C, Philips Z, Sullivan W, Dunlop WC. A systematic review of cost-effectiveness modeling of pharmaceutical therapies in neuropathic pain: variation in practice, key challenges, and recommendations for the future. J Med Econ. 2017 Feb;20(2):129-139. PMID: 27563752.
13: Cubo E, et al. Prospective study on cost-effectiveness of home-based motor assessment in Parkinson's disease. J Telemed Telecare. 2017 Feb;23(2):328-338. PMID: 27000142.
14: de Vos AS, Janssen MP, Zaaijer HL, Hogema BM. Cost-effectiveness of the screening of blood donations for hepatitis E virus in the Netherlands. Transfusion. 2017 Jan 31. PMID: 28144956.
15: Elbasha EH, Robertson MN, Nwankwo C. The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States. Aliment Pharmacol Ther. 2017 Feb;45(3):455-467. PMID: 27910116.
16: Elmallah RK, Chughtai M, Khlopas A, Bhowmik-Stoker M, Bozic KJ, Kurtz SM, Mont MA. Determining Cost-Effectiveness of Total Hip and Knee Arthroplasty Using  the Short Form-6D Utility Measure. J Arthroplasty. 2017 Feb;32(2):351-354. PMID: 27665243.
17: Floodeen H, Hallböök O, Hagberg LA, Matthiessen P. Costs and resource use following defunctioning stoma in low anterior resection for cancer - A long-term analysis of a randomized multicenter trial. Eur J Surg Oncol. 2017 Feb;43(2):330-336. PMID: 28069399.
18: Fust K, et al. Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models. Expert Rev Pharmacoecon Outcomes Res. 2017 Feb;17(1):39-52. PMID: 28064553.
19: Gilden DM, et al. Treatment patterns and cost-effectiveness of first line treatment of
advanced non-squamous non-small cell lung cancer in Medicare patients. J Med Econ. 2017 Feb;20(2):151-161. PMID: 27574722.
20: Grabner M, Winegar DA, Punekar RS, Quimbo RA, Cziraky MJ, Cromwell WC. Cost
Effectiveness of Achieving Targets of Low-Density Lipoprotein Particle Number Versus Low-Density Lipoprotein Cholesterol Level. Am J Cardiol. 2017 Feb 1;119(3):404-409. PMID: 27887691.
21: Groessl EJ, Sklar M, Laurent DD, Lorig K, Ganiats TG, Ho SB. Cost-Effectiveness of the Hepatitis C Self-Management Program. Health Educ Behav. 2017 Feb;44(1):113-122. PubMed PMID: 27206463.
22: Hagberg L, Hermansson L, Fredriksson C, Pettersson I. Cost-effectiveness of powered mobility devices for elderly people with disability. Disabil Rehabil Assist Technol. 2017 Feb;12(2):115-120. PMID: 25634493.
23: Hernandez I, Smith KJ, Zhang Y. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function. Thromb Res. 2017 Feb;150:123-130. PMID: 27771008.
24: Hojjat H, et al. Cost-effectiveness of routine computed tomography in the evaluation
of idiopathic unilateral vocal fold paralysis. Laryngoscope. 2017 Feb;127(2):440-444. PMID: 27601300.
25: Huang M, Lou Y, Pellissier J, Burke T, Liu FX, Xu R, Velcheti V. Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States. J Med Econ. 2017 Feb;20(2):140-150. PMID: 27571538.
26: Kajihara Y, Shimoyama T, Mizuki I. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication. Scand J Gastroenterol. 2017 Feb;52(2):238-241. PMID: 27806639.
27: Kearns B, Chilcott J, Whyte S, Preston L, Sadler S. Erratum to: Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation. BMC Med. 2017 Feb 3;15(1):31. PMID: 28158977.
28: Kievit W, Maurits JS, Arts EE, van Riel PL, Fransen J, Popa CD. Cost-Effectiveness of Cardiovascular Screening in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2017 Feb;69(2):175-182. PMID: 27159060.
29: Landfeldt E, Alfredsson L, Straub V, Lochmüller H, Bushby K, Lindgren P. Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis. Pharmacoeconomics. 2017 Feb;35(2):249-258. PMID: 27798808.
30: Largeron N, Petry KU, Jacob J, Bianic F, Anger D, Uhart M. An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany. Expert Rev Pharmacoecon Outcomes Res. 2017 Feb;17(1):85-98. PMID: 27366939.
31: Lawson R, Ryan J, King F, Goh JW, Tichy E, Marsh K. Cost Effectiveness of Naloxegol for Opioid-Induced Constipation in the UK. Pharmacoeconomics. 2017 Feb;35(2):225-235. PMID: 27663572.
32: Le P, Rothberg MB. Determining the Optimal Vaccination Schedule for Herpes Zoster: a Cost-Effectiveness Analysis. J Gen Intern Med. 2017 Feb;32(2):159-167. PMID: 27743284.
33: Leal J, et al. Cost-Effectiveness of Orthogeriatric and Fracture Liaison Service Models of Care for Hip Fracture Patients: A Population-Based Study. J Bone Miner Res. 2017 Feb;32(2):203-211.PMID: 27632945.
34: Leidner AJ, Chesson HW, Spradling PR, Holmberg SD. Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease. Appl Health Econ Health Policy. 2017 Feb;15(1):65-74. PMID: 27480538.
35: McLean TR. Interval Appendectomy: Cost-Effectiveness. J Am Coll Surg. 2017 Feb;224(2):219. PMID: 28129836.
36: Moradi-Lakeh M, Yaghoubi M, Hajebi A, Malakouti SK, Vasfi MG. Cost-effectiveness of aftercare services for people with severe mental disorders: an analysis parallel to a randomised controlled clinical trial in Iran. Health Soc Care Community. 2017 Feb 1. PMID: 28147433.
37: Mori T, Crandall CJ, Ganz DA. Cost-effectiveness of combined oral bisphosphonate therapy and falls prevention exercise for fracture prevention in the USA. Osteoporos Int. 2017 Feb;28(2):585-595. PMID: 27726000.
38: Muralidhar V, Nguyen PL. Maximizing resources in the local treatment of prostate cancer: A summary of cost-effectiveness studies. Urol Oncol. 2017Feb;35(2):76-85. PMID:27473636.
39: Neidell M, Lamster IB, Shearer B. Cost-effectiveness of diabetes screening initiated through a dental visit. Community Dent Oral Epidemiol. 2017 Feb 1. PMID: 28145564.
40: Osterberg EC, Murphy G, Harris CR, Breyer BN. Cost-effective Strategies for the Management and Treatment of Urethral Stricture Disease. Urol Clin North Am. 2017 Feb;44(1):11-17. PMID:27908365.
41: Panman C, Wiegersma M, Kollen BJ, Berger MY, Lisman-Van Leeuwen Y, Vermeulen
KM, Dekker JH. Two-year effects and cost-effectiveness of pelvic floor muscle training in mild pelvic organ prolapse: a randomised controlled trial in primary care. BJOG. 2017 Feb;124(3):511-520. PMID: 26996291.
42: Pedersen K, Sørbye SW, Kristiansen IS, Burger EA. Using novel biomarkers to triage young adult women with minor cervical lesions: a cost-effectiveness analysis. BJOG. 2017 Feb;124(3):474-484. PMID: 27264207.
43: Permsuwan U, Dilokthornsakul P, Thavorn K, Saokaew S, Chaiyakunapruk N. Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy versus sulfonylurea monotherapy for people with type 2 diabetes and chronic kidney disease in Thailand. J Med Econ. 2017 Feb;20(2):171-181. PMID: 27645706.
44: Qu XM, Louie AV, Ashman J, Wasif N. Cost-Effectiveness Analysis of Preoperative Versus Postoperative Radiation Therapy in Extremity Soft Tissue Sarcoma. Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):339-346. PMID: 28068242.
45: Ristau BT, Geynisman DM. Patient-reported and Cost-effectiveness Outcomes Are
Key to Determining the Optimal Therapeutic Sequence for Patients with Metastatic Renal Cell Carcinoma. Eur Urol. 2017 Feb;71(2):210-212. PMID: 27638095.
46: Robinson LA, Hammitt JK, Chang AY, Resch S. Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds. Health Policy Plan. 2017 Feb;32(1):141-145. PMID: 27452949.
47: Shafie AA, Ng CH, Tan YP, Chaiyakunapruk N. Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus. Pharmacoeconomics. 2017 Feb;35(2):141-162. PMID: 27752998.
48: Shao H, Zhai S, Zou D, Mir MU, Zawadzki NK, Shi Q, Liu S, Shi L. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus. Curr Med Res Opin. 2017 Feb;33(2):359-369. PMID: 27817216.
49: Shireman TI, et al. Cost-Effectiveness of Solitaire Stent Retriever Thrombectomy for Acute Ischemic Stroke: Results From the SWIFT-PRIME Trial (Solitaire With the Intention for
Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke). Stroke. 2017 Feb;48(2):379-387. PMID:28028150.
50: Smith SR, et al. Cost-Effectiveness of Tramadol and Oxycodone in the Treatment of Knee Osteoarthritis. Arthritis Care Res (Hoboken). 2017 Feb;69(2):234-242. PMID: 27111538.
51: Swart E, Laratta J, Slobogean G, Mehta S. Operative Treatment of Rib Fractures in Flail Chest Injuries: A Meta-analysis and Cost-Effectiveness Analysis. J Orthop Trauma. 2017 Feb;31(2):64-70. PMID: 27984449.
52: Vidal J, Slof J, Serrano D, Marqués T, Kumru H, Benito-Penalva J. Cost-effectiveness of Intrathecal Baclofen Therapy in severe refractory non-focal disabling spasticity: a Spanish hospital perspective. Expert Rev Pharmacoecon Outcomes Res. 2017 Feb;17(1):67-76. PMID: 27142176.
53: Vodicka EL, et al. Costs of integrating cervical cancer screening at an HIV clinic in Kenya. Int J Gynaecol Obstet. 2017 Feb;136(2):220-228.
54: Wang J, Chmielowski B, Pellissier J, Xu R, Stevinson K, Liu FX. Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States. J Manag Care Spec Pharm. 2017 Feb;23(2):184-194. PMID: 28125365.
55: Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD,Campbell JD. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol. 2017 Feb;118(2):220-225. PMID: 27923549.
56: Yanagi Y, Fukuda A, Barzey V, Adachi K. Cost-effectiveness of intravitreal aflibercept versus other treatments for wet age-related macular degeneration in Japan. J Med Econ. 2017 Feb;20(2):204-212. PMID: 27701921.
57: Yoshimura M, Moriwaki K, Noto S, Takiguchi T. A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women. Osteoporos Int. 2017 Feb;28(2):643-652. PMID: 27743068.
58: Zhong Y, Cohen JT, Goates S, Luo M, Nelson J, Neumann PJ. The Cost-Effectiveness of Oral Nutrition Supplementation for Malnourished Older Hospital Patients. Appl Health Econ Health Policy. 2017 Feb;15(1):75-83. PMID: 27492419.
By CEA Registry Team on 2/3/2017 11:40 AM
This week we highlighted findings from recently published cost-effectiveness studies:
  • Various colorectal cancer screening strategies compared on relative impact: Among thirteen different screening strategies for colorectal cancer, colonoscopy was determined to be the most cost-effective strategy (1)
  • Addition of bedaquiline to treatment regimen of multidrug-resistant tuberculosis found to be effective: Adding bedaquiline to the treatment regimen of multidrug-resistant tuberculosis in select high burden countries led to improvements in health outcomes and reductions in healthcare costs (9)
  • Initial plus extended treatment with apixaban for the treatment of venous thromboembolism found to be cost-effective: In the UK, initial plus extended treatment with apixaban for the treatment and prevention of venous thromboembolism was found to be a cost-effective alternative to low-molecular-weight heparin and vitamin K antagonist (8)
See below for a full list of all cost-utility studies and selected reviews and editorials published January 23-27, 2017.  To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry.  Follow us on Twitter (@TuftsCEVR) and Facebook.
1: Barzi A, Lenz HJ, Quinn DI, Sadeghi S. Comparative effectiveness of screening strategies for colorectal cancer. Cancer. 2017 Jan 24. PMID: 28117881.
2: Brar H, Hogen L, Covens A. Cost-effectiveness of sentinel node biopsy and pathological ultrastaging in patients with early-stage cervical cancer. Cancer. 2017 Jan 24. PMID: 28117888.
3: Favato G, Noikokyris E, Vecchiato R. Ecological validity of cost-effectiveness models of universal HPV vaccination: a protocol for a systematic review. Syst Rev. 2017 Jan 25;6(1):17. PMID: 28118846.
4: Goulding JM, Harper N, Kennedy L, Martin KR. Cost-effectiveness in Psychodermatology: A Case Series. Acta Derm Venereol. 2017 Jan 25. PMID: 28120000.
5: Guarda AS, Schreyer CC, Fischer LK, Hansen JL, Coughlin JW, Kaminsky MJ, Attia E, Redgrave GW. Intensive treatment for adults with anorexia nervosa: The cost of weight restoration. Int J Eat Disord. 2017 Jan 27. PMID: 28130794.
6: Hunt B, Vega-Hernandez G, Valentine WJ, Kragh N. Evaluation of the long-term cost-effectiveness of liraglutide versus lixisenatide for treatment of type 2diabetes mellitus in the UK setting. Diabetes Obes Metab. 2017 Jan 26. PMID: 28124820.
7: Kearns B, Rafia R, Leaviss J, Preston L, Brazier JE, Palmer S, Ara R. The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation. BMC Health Serv Res. 2017 Jan 24;17(1):78. PMID: 28118838.
8: Lanitis T, Leipold R, Hamilton M, Rublee D, Quon P, Browne C, Cohen AT. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences. BMC Health Serv Res. 2017 Jan 23;17(1):74. PMID: 28114939.
9: Lu X, Smare C, Kambili C, El Khoury AC, Wolfson LJ. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries. BMC Health Serv Res. 2017 Jan 26;17(1):87.PMID: 28122562.
10: Sartori AM, Rozman LM, Decimoni TC, Leandro R, Novaes HM, de Soárez PC. A systematic review of health economic evaluations of vaccines in Brazil. Hum Vaccin Immunother. 2017 Jan 27:0. PMID: 28129026.
11: Sawad AB, Seoane-Vazquez E, Rodriguez-Monguio R, Turkistani F. Cost-effectiveness of different strategies for treatment relapsing-remitting multiple sclerosis. J Comp Eff Res. 2017 Jan 25. PMID: 28118731.
12: Schilling C, Petrie D, Dowsey MM, Choong PF, Clarke P. The Impact of Regression to the Mean on Economic Evaluation in Quasi-Experimental Pre-Post Studies: The Example of Total Knee Replacement Using Data from the Osteoarthritis Initiative. Health Econ. 2017 Jan 27. PMID: 28127856.
13: Sharma M, Seoud M, Kim JJ. Cost-effectiveness of increasing cervical cancer screening coverage in the Middle East: An example from Lebanon. Vaccine. 2017 Jan 23;35(4):564-569. PMID: 28017434.
14: Stark Z, Schofield D, Alam K, Wilson W, Mupfeki N, Macciocca I, Shrestha R, White SM, Gaff C. Prospective comparison of the cost-effectiveness of clinical whole-exome sequencing with that of usual care overwhelmingly supports early use and reimbursement. Genet Med. 2017 Jan 26. PMID: 28125081.
15: Wang Y, Yan BP, Liew D, Lee VW. Cost-effectiveness of cytochrome P450 2C19 *2 genotype-guided selection of clopidogrel or ticagrelor in Chinese patients with acute coronary syndrome. Pharmacogenomics J. 2017 Jan 24. PubMed PMID: 28117433.
By CEA Registry Team on 2/2/2017 11:15 AM
 By Elle Pope
A new commentary published today explores the meaning and impact, as well as remaining questions surrounding the passage of the 21st Century Cures Act and corresponding FDA draft guidance on communications of healthcare economic information.


By CEA Registry Team on 1/24/2017 3:44 PM
By Paige Lin, Ph.D.

Would you test your newborn for a rare but serious genetic disorder for which no direct treatment is available?
In a paper published this week in Pediatric Neurology, my colleagues and I demonstrate that most people would prefer testing their newborn for Spinal Muscular Atrophy (SMA) and express a reasonably high willingness to pay for the test, even in the absence of direct treatment [1].
SMA, the most fatal genetic neuromuscular disease among children, affects approximately 1 in 10,000 infants [2]. While early diagnosis can provide a window of opportunity for early intervention, current mandatory newborn screening programs in the United States do not require SMA testing primarily due to lacking disease-modifying therapy, until very recently [3].
In order to gauge the public’s preferences for SMA testing for newborns, we surveyed 982 US adults and asked how much, if any, they would pay out-of-pocket for the test using a bidding game approach. Each respondent was presented with two scenarios: the standard of care (no available treatment) and one of three hypothetical substitute scenarios that were randomly assigned:
  1. Improved functioning: New treatment improves functioning, but does not affect survival
  2. Improved survival: New treatment may improve survival, but it does not improve functioning
  3. Improved functioning and survival: New treatment would improve both functioning and survival
From this survey, we found that most people (79%) would prefer to test their newborn for SMA even without a treatment available.  A greater proportion (85% to 86%) would prefer the test if a treatment improved either functioning or survival, respectively. The vast majority (87%) would opt to pay for the test if an available treatment improved both functioning and survival. Respondents also demonstrated an equitably high willingness-to-pay value for the test (average $253 to $297).
Despite preferences for the test information, adding SMA to national newborn screening programs remains controversial because currently there is insufficient evidence on long-term patient outcomes as a result of early identification and early treatment for SMA at a population level. Our results provide insight into how the general public views the value of SMA testing, and how potential treatment benefits may affect their testing decisions.  Our findings add a new dimension to the discussions parents, physicians, and policymakers should have on whether SMA screening should be legislatively mandated.    
Tufts Medical Center received research funding support for this study from Biogen, which markets the first FDA-approved SMA treatment SPINRAZA™ (nusinersen).
[1] Lin PJ, Yeh WS, Neumann PJ. Willingness to Pay for a Newborn Screening Test for Spinal Muscular Atrophy. Pediatr Neurol. 2017 Jan;66:69-75. doi: 10.1016/j.pediatrneurol.2016.09.008. PubMed PMID: 27769729.
[2] Dolgin E. Call in the backup. Nat Med. 2012; 18:1602-1606.
[3] U.S. Food & Drug Administration. FDA approves first drug for spinal muscular atrophy [Press release].

Please view the blog archive for earlier entries

Search This Blog


Blog Archive

<September 2017>
August, 2017 (1)
June, 2017 (1)
May, 2017 (4)
April, 2017 (4)
March, 2017 (3)
February, 2017 (6)
January, 2017 (6)
December, 2016 (4)
November, 2016 (4)
October, 2016 (3)
September, 2016 (2)
August, 2016 (1)
June, 2016 (1)
May, 2016 (1)
February, 2016 (2)
November, 2015 (1)
September, 2015 (2)
August, 2015 (1)
July, 2015 (2)
June, 2015 (5)
May, 2015 (6)
April, 2015 (4)
March, 2015 (6)
February, 2015 (6)
January, 2015 (5)
December, 2014 (5)
November, 2014 (2)
October, 2014 (5)
September, 2014 (7)
August, 2014 (5)
July, 2014 (3)
June, 2014 (2)
May, 2014 (1)
April, 2014 (3)
March, 2014 (3)
February, 2014 (3)
November, 2013 (1)
October, 2013 (4)
September, 2013 (4)
August, 2013 (9)
July, 2013 (7)
June, 2013 (6)
May, 2013 (4)
April, 2013 (4)
March, 2013 (6)
February, 2013 (7)
January, 2013 (5)
December, 2012 (6)
November, 2012 (8)
October, 2012 (11)
September, 2012 (9)
August, 2012 (10)
July, 2012 (11)
June, 2012 (10)
May, 2012 (10)
April, 2012 (9)
March, 2012 (9)
February, 2012 (7)
January, 2012 (4)
December, 2011 (3)
November, 2011 (5)
October, 2011 (8)
September, 2011 (6)
August, 2011 (4)
July, 2011 (10)
June, 2011 (8)
May, 2011 (10)
April, 2011 (9)
March, 2011 (9)
February, 2011 (8)
January, 2011 (6)
December, 2010 (7)
November, 2010 (10)
October, 2010 (7)
September, 2010 (5)
August, 2010 (8)
July, 2010 (13)
June, 2010 (8)
May, 2010 (9)
April, 2010 (7)
March, 2010 (5)
February, 2010 (9)
January, 2010 (2)
August, 2009 (1)
May, 2009 (1)
April, 2009 (1)
March, 2009 (1)
November, 2008 (1)